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resumo 
 
 
Uma das características principais da doença de Parkinson é o aparecimento 
de inclusões citoplasmáticas, chamadas corpos de Lewy, maioritariamente nos 
neurónios dopaminérgicos remanescentes, no tronco cerebral dos pacientes 
afetados. Várias proteínas têm sido identificadas nos corpos de Lewy, mas o 
seu mecanismo de formação permanece por clarificar. Entre as várias 
proteínas já identificadas encontram-se a sinfilina-1, uma proteína interactora 
da α-sinucleina, e a sinfilina-1A, uma variante da sinfilina-1. Ambas têm sido 
consideradas elementos chave na doença de Parkinson, já que a sua 
sobreexpressão em células embrionárias 293 de rim humano, com ou sem a α-
sinucleina, conduz à formação de inclusões citoplasmáticas parecidas com 
corpos de Lewy. Posto isto, têm sido envidados esforços no sentido de 
clarificar os mecanismos reguladores da agregação da sinfilina-1 e da sinfilina-
1A, como forma de revelar novos aspetos da formação dos corpos de Lewy.    
 
Embora tenham sido descritas cinases capazes de fosforilar a sinfilina-1, não 
há informações concretas sobre as fosfatases responsáveis pela sua 
desfosforilação. Este vazio começou a ser preenchido com a identificação da 
sinfilina-1A como uma nova proteína interactora da fosfoproteína fosfatase 1 
em cérebro humano, através do sistema dois híbrido de levedura. Deste modo, 
no presente trabalho, procede-se ao estudo da função fisiológica do complexo 
sinfilina-1A/fosfoproteína fosfatase 1, demonstrando-se a capacidade da 
sinfilina-1A de recrutar de forma específica a fosfoproteína fosfatase 1 para 
corpos de inclusão, com recurso a imunofluorescência. Adicionalmente, as 
consequências do bloqueio desta interação são exploradas utilizando um 
mutante da sinfilina-1A incapaz de interagir com a fosfoproteína fosfatase 1, 
revelando um aumento das propriedades agregativas da sinfilina-1A. 
Finalmente, também é avaliada a capacidade de a sinfilina-1A selvagem e 
mutada produzirem agressomas, quando sobreexpressas e sem inibição do 
proteassoma, mas os resultados não são claros e não permitem a 
classificação das inclusões documentadas no presente trabalho como 
agressomas. Em conjunto, estes resultados sugerem que a sinfilina-1A tem a 
capacidade de afetar o endereçamento da fosfoproteína fosfatase 1 nas 
células, sendo a formação de corpos de inclusão dependente e, mais 
concretamente, controlada pela atividade da fosfoproteína fosfatase 1. Postula-
se que um menor endereçamento da fosfoproteína fosfatase 1 para os corpos 
de inclusão conduza a estados hiperfosforilados que favorecem a agregação 
proteica. 
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abstract 
 
One of the major Parkinson’s disease hallmarks is the development of 
cytoplasmic inclusions, termed Lewy bodies, mainly within surviving neurons in 
the brainstem of affected patients. Many proteins have been identified in the 
Lewy bodies, but their formation mechanism remains unclear. Among the 
proteins already identified in the Lewy bodies are synphilin-1, a α-synuclein-
interacting protein, and synphilin-1A, a synphilin-1 splice variant. Synphilin-1 
and synphilin-1A have been considered key elements in Parkinson’s disease 
as their overexpression in human embryonic kidney 293 cells, with or without α-
synuclein, leads to the formation of Lewy body-like cytoplasmic inclusions. 
Therefore, efforts have been made to clarify the regulatory mechanisms behind 
synphilin-1 and synphilin-1A aggregation as a means to uncover new aspects 
of Lewy bodies formation. 
 
Although kinases able to phosphorylate synphilin-1 have been described, there 
are no specific data concerning the phosphatases responsible for its 
dephosphorylation. This gap was filled with the identification of synphilin-1A as 
a novel phosphoprotein phosphatase 1-interacting protein in human brain, 
through yeast two hybrid. Hence, in the present work, the physiological role of 
synphilin-1A/phosphoprotein phosphatase 1 complex is studied, being 
demonstrated the ability of synphilin-1A to specifically target phosphoprotein 
phosphatase 1 to inclusion bodies, using immunofluorescence experiments. 
Moreover, the consequences of disrupting this interaction are explored using a 
synphilin-1A mutant unable to interact with phosphoprotein phosphatase 1, 
revealing an enhancement of synphilin-1A aggregative properties. Also, the 
ability of wild type synphilin-1A and the mutant form to produce aggresomes 
upon overexpression and without proteasome inhibition is addressed but the 
results are unclear, does not allowing the classification of the inclusions 
documented in this work as aggresomes. All together, these results suggest 
that synphilin-1A is able to affect phosphoprotein phosphatase 1 targeting 
within cells, being inclusion bodies formation dependent and, most specifically, 
controlled by phosphoprotein phosphatase 1 activity. It is postulated that 
decreased phosphoprotein phosphatase 1 recruitment to inclusion bodies 
produces hyperphosphorylated states that favor protein aggregation.       
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1.1 PARKINSON’S DISEASE OVERVIEW 
1.1.1 Parkinson’s Disease: Basics and Epidemiology 
Parkinson’s disease (PD) is a neurodegenerative motor disorder first described in 1817 by 
James Parkinson in “An Essay on the Shaking Palsy”[1]. According to epidemiological data, PD is 
the second most common neurodegenerative disorder after Alzheimer’s disease, affecting about 
0,3% of the whole population in industrialized countries
[2, 3]
. Moreover, the likelihood of 
developing PD increases with age: prevalence rises from 1% in individuals over 60 years of age to 
4% in individuals over 80
[3, 4]
. Indeed, the mean age of onset is around 60 years, being the 
incidence between 8 and 18 per 100,000 person/years
[3, 4]
. Thence, population aging has led to an 
increasing concern on this pathology and to more investment in its understanding. 
Two main types of PD are considered according to age of onset: (1) sporadic late-onset PD 
which accounts for 90% of the cases, with onset over the age of 50; and (2) rare early-onset PD 
which accounts for 5-10% of all cases, occurring before the age of 50
[3-5]
. 
1.1.2 Parkinson’s Disease: Pathological and Clinical Hallmarks 
In terms of pathological hallmarks, PD is mainly characterized by progressive degeneration 
and loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) while surviving 
neurons develop proteinaceous deposits in the cytoplasm (Lewy bodies - LBs) and within neuritis 
(Lewy neuritis)
[6-8]
. However, neuronal loss and LBs formation are also seen in other brain regions 
besides SNpc
[8, 9]
. Indeed, Braak and colleagues have found evidences that Lewy pathology in PD 
is frequently ordered and sequential, beginning in the olfactory region and/or in the dorsal motor 
nucleus of the vagus (stages I-II). Then, in the midstage of the disease, SNpc is affected together 
with other upper brainstem regions (stages III-IV), being the cerebral hemispheres involved only in 
latter stages (stages V-VI)
[8, 9]
. Dopaminergic neurons loss leads to dopamine deficiency in the 
striatum, producing a well characterized phenotype termed parkinsonism, which includes resting 
tremor, rigidity, bradykinesia and postural instability (Figure 1)
[10, 11]
. Furthermore, PD patients 
often suffer from non-motor symptoms such as autonomic dysfunction
[12]
, depression and even 
dementia
[2, 10, 11]
.  
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Figure 1 – Neuropathology of Parkinson’s disease. In normal condition, dopaminergic neurons located in the 
substantia nigra pars compacta project to putamen. These projections modulate striatum activity. Upon activation, 
putamen inhibits internal globus pallidus, decreasing the inhibition exerted by internal globus pallidus in thalamus. 
Thalamic deinhibition allows the cortical excitation necessary for movement initiation. In PD patients, substantia nigra 
pars compacta looses pigmentation due to neuromelanin-rich, dopaminergic neurons loss, reducing putamen activation. 
This event reinforces internal globus pallidus inhibition on thalamus, causing difficulties in movement initiation[6]. 
(SNpc, substantia nigra pars compacta; Pu, putamen; GPi, internal globus pallidus; Th, thalamus. Dash arrows represent 
PD affected pathways. For simplification, only the direct pathway is represented.)   
1.1.3 Parkinson’s Disease: Etiology and Pathogenesis 
Despite all knowledge concerning clinical and pathological hallmarks, PD etiology remains 
in debate. Currently, there are three main suggested causes for PD development: (1) environmental 
factors (such as exogenous toxins); (2) genetic factors; and (3) endogenous toxins
[2, 6, 13, 14]
.  
Numerous studies have presented evidence suggesting the role of exogenous toxins for PD 
development, particularly 1-methyl-4-phenyl-1,2,3,6 tetrahydropiridine (MPTP)
[15]
, paraquat and 
rotenone
[6, 16]
. Therefore, these compounds are traditionally used to produce PD-animal models, 
being able to interfere with mitochondrial function and producing oxidative stress
[6]
. After a period 
in which the “environmental toxin hypothesis” was the main explanation for PD, a revolution has 
occurred in 1997 with the discovery that mutations in the gene for α-synuclein (α-syn) were able to 
produce familial forms of this pathology
[17]
. After that, many other mutated proteins associated to 
inherited rare forms of PD have been identified
[18]
. Besides exogenous toxins and genetics, a third 
hypothesis suggests that distortions in the normal metabolism of some substances, as dopamine, 
could produce endogenous harmful compounds able to take part in the degeneration process
[14]
.  
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Whichever the etiological factor to initiate sporadic PD, there are two main explanations for 
its pathogenesis. The first one emphasizes protein misfolding and proteasome/lysosome 
dysfunction
[6, 19-21]
, while the second one emphasizes mitochondrial dysfunction, oxidative stress 
and dopamine oxidation
[6, 22, 23]
. Obviously, they are not mutually exclusive, being the present aim 
in PD research to identify the sequence of these events and if they ultimately engage in a common 
mechanism for cell death (Figure 2).  
 
Figure 2 – Parkinson’s disease pathogenesis. A growing body of evidence suggests that the accumulation of misfolded 
proteins is likely to be a key event in PD pathogenesis. Protein misfolding could be induced by genetic mutations 
producing aggregation-prone proteins (α-synuclein) or interfering with proteins involved in quality control and misfolded 
protein degradation (Parkin and UCH-L1). On the other hand, oxidative stress related with mitochondrial dysfunction and 
abnormal dopamine metabolism may also produce protein misfolding. It is unclear if misfolded proteins cause toxicity 
directly or via aggregates formation. The role of Lewy bodies remains to be clarified as some studies suggest a protective 
role while others suggest that Lewy bodies display toxicity. Other possible mechanisms of promoting cell death include 
ATP depletion and apoptosis[6]. (α-syn, α-synuclein; ROS, reactive oxygen species; UCH-L1, ubiquitin carboxyl-terminal 
hydrolase isozyme L1. Dash arrows represent the main events that need to be clarified.)   
Despite the relevance of mitochondrial integrity, the hypothesis concerning protein 
misfolding and proteasome/lysosome dysfunction as explanation for PD pathogenesis will be 
emphasized in the present work. Indeed, neurons are cells incapable of full regeneration, being 
prone to suffer from protein accumulation due to their long life span. Furthermore, the production 
of abnormal proteins is prominent in the central nervous system (CNS) due to the high oxidative 
metabolism in neuronal cells
[24]
. Taken together, all these features determine that protein clearance 
is vital for proteostasis and neuron’s survival.   
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1.2 PROTEOLYTIC STRESS AND AGGRESOMES FORMATION 
Proper folding is vital for protein function. Nevertheless, the energy levels that separate 
native and non-native conformations are small enough to allow even native proteins to unfold 
under specific stress conditions
[25, 26]
. Thence, under stress conditions, some proteins suffer 
misfolding, being converted in toxic, aggregation-prone forms which must be properly cleared in 
order to avoid cellular toxicity
[26]
. 
1.2.1 Preventing Proteolytic Stress: Chaperones, UPS and ALS 
Preventing the accumulation of aggregation-prone proteins is the most effective way to 
control protein aggregation which is achieved by folding facilitation through chaperones 
intervention and proteolytic degradation of abnormal proteins
[26, 27]
. Two are the main chaperone 
classes that prevent misfolded proteins accumulation: heat shock proteins (HSP) HSP60 and 
HSP70
[28, 29]
. However, misfolded proteins that could not be refolded are usually degraded by 
cytosolic ATP-dependent AAA+ proteases, such as the 26S proteasome
[26]
. 
The ubiquitin-proteasome system (UPS) is the major system in eukaryotic cells responsible 
for the disposal of abnormal and soluble proteins as well as short-lived regulatory proteins from the 
nucleus, cytosol and endoplasmic reticulum (ER). This system comprises three enzymes, i.e. the 
ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin-protein 
ligase (E3), in combination with the 26S proteasome
[30]
. The first three enzymes target proteins for 
proteasomal degradation by addition of ubiquitin moieties. On the other hand, the 26S proteasome 
possesses the degradation machinery, comprising a catalytic core (the 20S proteasome) and a 
regulatory cap (PA700) that regulates proteolysis. The catalytic core houses 3 proteases 
(chymotripsin-like, trypsin-like and peptidyl-glutamyl-peptide hydrolytic proteases) which degrade 
targeted proteins to small peptides and amino acids
[24]
. 
Despite the importance of UPS, cells possess another protein clearance system, the 
autophagy/lysosomal system (ALS). ALS is the major system responsible for disposal of insoluble 
bulk material such as protein aggregates and even unwanted organelles. This system requires the 
formation of spherical structures that contain acidic hydrolases able to breakdown macromolecules 
[26, 31]
.  
Although there is cellular machinery responsible for protein clearance, when the generation 
of misfolded proteins exceeds the refolding or degradative capacity of the cell, protein aggregates 
accumulate. In this case, cells become under proteolytic stress, a feature clearly behind PD 
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pathogenesis, as mutations affecting UPS components, lysosomes and some aggregation-prone 
proteins produce familial cases of PD
[32]
. 
1.2.2 Dealing with proteolytic stress: aggresomes formation 
When quality-control systems are overrun, protein aggregation takes place. However, recent 
data have suggested that even protein aggregation is a regulated process within cells
[26]
.  
Indeed, upon expression of some heterologous proteins or proteasome inhibition, 
mammalian cells produce specialized, non-permanent inclusion bodies in the cytoplasm termed 
aggresomes
[33, 34]
. These inclusions appear mainly as single spheres (1-3µm in diameter) or ribbons, 
being located to an indentation of the nuclear envelope at the microtubule-organizing centre 
(MTOC) and are surrounded by a cage-like shell made of vimentin
[34, 35]
. Aggresomes formation 
usually begins in the cell periphery through the assembly of small aggregates
[34]
 which are 
transported to the final perinuclear site at the MTOC in a dynein-based manner
[36]
. Besides the 
dynein motor complex, histone deacetylase 6 (HDAC6), ataxin-3 and ubiquilin-1 are also important 
for recognition and transportation of cargo proteins into aggresomes
[37-39]
. Interestingly, some 
observations have suggested a potential role for Parkin, an E3 ubiquitin ligase, in substrates 
targeting into aggresome-autophagy pathway through K63-linked polyubiquitylation of misfolded 
proteins
[37]
. In light of that, in order to classify an inclusion as aggresome, two main criteria must 
be fulfilled: (1) the inclusion must co-localize with MTOC markers (such as γ-tubulin); and (2) its 
formation must be dependent on microtubules dynamics (being inhibited by drugs able to interfere 
with microtubules polymerization/depolymerization)
[40, 41]
.     
Curiously, aggresome formation is not a dead-end situation. Actually, heat shock proteins 
and components of the UPS are recruited to these inclusions to facilitate protein clearance
[26]
. 
Furthermore, aggresomes could be interesting in PD studies because it has been suggested that 
LBs, the typical PD inclusions, are a form of aggresome. Indeed, they have aggresomal appearance 
and contain centrosome/aggresome-specific proteins (as γ-tubulin) together with heat shock 
proteins and UPS elements commonly seen in aggresomes. Finally LBs reveal high levels of 
oxidized, phosphorylated and ubiquitylated proteins that normally do not accumulate in cells. It has 
been suggested that LBs might be cytoprotective under stress conditions, enhancing misfolded 
proteins clearance
[24, 42, 43]
. 
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1.3 LEWY BODIES OVERVIEW 
LBs are cytoplasmic rounded inclusions of 8-30 µm in diameter first described by Friedrich 
Lewy
[44]
 after analysis of several brains from PD patients. Since their discovery, LBs were 
subjected to intensive study and other inclusion bodies were described for other neurodegenerative 
disorders besides PD. Nevertheless, after many years of study, the actual function of these 
inclusions is still highly controversial as some claim that inclusion bodies are part of the 
pathological process while others suggest a protective role against toxicity
[45]
. 
1.3.1 Lewy Bodies Structure and Classification 
LBs may be classified according to their morphology and location in two main types: (1) 
brainstem (classic) LBs; and (2) cortical LBs
[46]
. The brainstem LBs usually occur in the brainstem 
nuclei and diencephalon, being spherical cytoplasmic inclusions characterized by hyaline 
eosinophilic cores, concentric lamellar bands, narrow pale halos and immunoreactivity for α-syn 
and ubiquitin (Figure 3A)
[47]
. By contrast, the cortical type is usually devoid of the halo (Figure 
3B)
[48]
. 
 
Figure 3 – Lewy bodies structure and classification. A) Classical Lewy body in a neuron in the dorsal raphe nuclei. B) 
Cortical Lewy body in a neuron in the medial temporal lobe. (Adapted from[49])  
In terms of composition, LBs are a rather heterogeneous mixture of insoluble proteins and 
lipids, being α-syn derivatives their main components. However, apart from α-syn, a huge number 
of proteins have been identified so far, belonging to many different classes and families. Indeed, 
these proteins include: (1) UPS-related proteins (ubiquitin, ubiquitylated proteins, ubiquitin ligases, 
proteasome elements, parkin and DJ-1); (2) cytoskeletal proteins (neurofilaments, tubulins, 
microtubule associated proteins and gelsolin); (3) protein kinases and phosphatases; (4) chaperones 
(HSP70 and HSP90); (5) torsin A, 14-3-3; (6) inflammatory proteins as complements; (7) α-syn-
binding proteins as synphilin-1and microtubule-associated protein 1B (MAP1B); (8) Alzheimer’s 
disease related proteins (microtubule-associated protein tau and Aβ); (9) apoptotic proteins (Bcl-2 
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associated death proteins and extracellular regulated kinases); and (10) other proteins as 
cytochrome c, transglutaminase and glutathione peroxidase. Furthermore, these proteins may be 
ubiquitylated, phosphorylated, nitrated and/or oxidized
[2, 50-52]
.  
1.4 MOLECULAR BASIS OF PARKINSON’S DISEASE: ALPHA-SYNUCLEIN  
Despite the complexity of PD, α-syn has been gathering great attention because there is 
evidence that it could be a major element in PD pathogenesis. Indeed, some familial forms of the 
disease are associated with mutations in the gene SNCA, in which α-syn is encoded[17, 53]. These 
mutations could be point mutations (A30P, A53T and E46K) or locus duplications and 
triplications, all of them causing parkinsonism with an autosomal dominant pattern of 
inheritance
[2]
. Moreover, α-syn can also be detected in LBs even in sporadic cases of PD[53]. Taking 
in account the relevance of α-syn, efforts have been made in order to uncover its physiological 
function and its role in LBs formation.  
1.4.1 α-synuclein structure and function 
α-syn is a small, insoluble, intrinsically unfolded protein of 140 amino acids encoded by the 
SNCA gene located at chromosome 4 (Figure 4)
[54, 55]. In physiological conditions, α-syn is 
distributed to almost all subcellular compartments within neurons, but is enriched in the nucleus 
and presynaptic terminals
[56, 57]
.  
 
Figure 4 – α-synuclein structure. The amphipatic N-terminal region (dark gray) allows the association between α-
synuclein and lipid layers. The hydrophobic NAC (non-Aβ component) region (medium gray) comprises the aggregative-
prone domain of α-synuclein. The acidic C-terminal region (light gray) does not associate with membranes and seems to 
be important for chaperone-like functions of α-synuclein. Upon association with lipid micelles or membranes, α-
synuclein acquires a secondary structure with two α-helixes. The point mutations A30P, A53T and E46K are located in 
the amphipatic N-terminal region. On the other hand, the acidic C-terminal region balances aggregative properties of 
NAC region, hindering α-synuclein spontaneous aggregation[58].  
Although its function remains unclear, it has been suggested that α-syn has two major action 
sites within cells, namely presynaptic terminals
[57]
 and plasma membrane
[59]
. At the presynaptic 
terminals, α-syn is thought to modulate synaptic vesicle function as it reversibly binds to brain 
vesicles and components of the vesicular trafficking machinery
[57, 60, 61]
. On the other hand, some 
data suggest an additional role in plasma membrane dynamics, probably protein trafficking. This is 
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consistent with some results which demonstrate α-syn involvement in the membrane localization of 
dopamine active transporter (DAT)
[62]
. Many other functions are suggested but they are beyond the 
scope of this introduction
[63, 64]
.   
1.4.2 α-synuclein in Parkinson’s Disease 
A growing body of evidence favors a critical, although in most cases, not necessarily a prime 
causal role of α-syn in PD pathogenesis. Indeed, families bearing SNCA mutations usually develop 
PD, being mutated α-syn the causal factor in these cases[2, 17]. Nevertheless, in sporadic patients in 
whom α-syn is not mutated, disease causes and mechanism seem to converge primarily around 
oxidative stress and impairment of protein catabolism. It is not clear if these causalities involve α-
syn from the beginning or if defects in the handling of this protein just favor disease progression 
and neurons damage
[65]
. 
Findings suggesting a critical role of α-syn in PD include: (1) the presence of α-syn 
inclusions in the brain areas affected by PD; (2) the inheritance of PD in families bearing SNCA 
mutations; (3) the ability of α-syn to produce toxic oligomers, protofibrils and fibrils; (4) the 
formation of α-syn aggregates in chemically induced animal models of PD; and (5) neuronal 
dysfunction, synaptic terminals loss, neurons loss and damage to lysosomes upon α-syn 
overexpression in animal and cell models. Nevertheless, any of these studies present an 
unequivocal proof for a prime causal role of wild type α-syn in idiopathic PD[65]. 
Assuming that α-syn is involved in PD pathogenesis, it is important to evaluate which forms 
could be toxic. One interesting hypothesis postulates that post-translational modifications and 
molecular crowding of α-syn accelerate the formation of β-sheet-rich, spherical protofibrils. Latter, 
also chain-like and annular protofibrils are formed. Annular protofibrils are able to permeabilize 
membranes, allowing dopamine release within neurons which enhances oxidative stress. This 
hypothesis is corroborated by a cell-based study in which is proven that prefibrillar aggregates are 
able to produce toxicity in the absence of insoluble inclusions
[65]
.  
Besides soluble forms, α-syn is also able to form fibrillar and/or amorphous proteinase-
resistant aggregates. These forms also display toxicity but perhaps only in latter stages of the 
disease process. Indeed, in early phases, they might act as cellular “sinks”, trapping soluble 
oligomers. Obviously, these insoluble forms take part in LBs formation
[45, 65]
. 
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1.5 MOLECULAR BASIS OF PARKINSON’S DISEASE: SYNPHILIN-1 
In attempting to uncover α-syn function, a yeast two hybrid screen was performed aiming the 
identification of some α-syn-interacting proteins[53]. Interestingly, a novel protein, synphilin-1 
(Sph1), has come into light and nowadays is intensively studied in order to clarify the mechanism 
of LBs formation. The importance of Sph1 for PD pathogenesis comes from its ability to interact 
with α-syn both in vivo and in vitro[53, 66]. Moreover, both proteins have nearly the same subcellular 
localization and both can be detected in LBs
[67-69]
. At the beginning no mutations or polymorphisms 
in Sph1 were associated with familial cases of PD
[70-72]
. Nevertheless, the R621C mutation was 
documented latter in two apparently unrelated German PD patients reinforcing the suggestion that 
Sph1 may actually play a role in PD
[73]
. Indeed, this mutation seems to represent a potential 
susceptibility factor for PD development. 
1.5.1 Synphilin-1 structure and function 
Sph1 is encoded by the SNCAIP gene, which is located in the chromosome 5 near markers 
WI-4673 and AFMB352XH5, and its open reading frame is contained within 10 exons
[70]
. As a 
protein, Sph1 is made of 919 amino acids and is composed by different structural domains: 
ankyrin-repeats, a coiled-coil domain and a putative ATP, GTP-binding domain (Figure 5)
[53]
. 
 
Figure 5 – SNCAIP gene and synphilin-1 structure. Sph1 coding region begins in the middle of exon 1 and ends 
within the very first few nucleotides of exon 10. Exons 4 through 7 contain the ankyrin-like repeats and a portion of the 
coiled-coil domain, while exon 8 contains the remainder of the coiled-coil domain and the ATP, GTP-binding domain.  In 
this figure, the location of the RVTF (the PPP1 binding domain) motif is also specified at the C-terminus. Of note, Sph1 
possesses many domains able to participate in protein-protein interactions, reinforcing its possible function as a linking 
protein[70, 74]. (ANK, ankyrin-like repeats; CC, coiled-coil domain; ATP/GTP BM, ATP, GTP-binding domain.)   
In terms of tissue and subcellular localization, Sph1 shows a distribution similar to α-syn 
suggesting a relationship between these proteins. Indeed, Sph1 is widely distributed in brain and 
highly enriched in neurons, being found in the cell bodies of immature neurons and suffering 
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redistribution towards the presynaptic nerve terminals during development. Thence, Sph1 is 
particularly abundant in the neuropil and is located in the vicinity or associated to synaptic 
vesicles
[70, 75]
. Interestingly, a contrasting observation has come from a rat model in which Sph1 
remains in the soma of substantia nigra neurons, contributing to the susceptibility of this area to 
LBs formation
[75]
.  
Although its actual function remains elusive, Sph1 is a synaptic vesicle-binding protein 
thought to anchor α-syn to vesicle membranes[75] and may affect dopamine release as well[76].  
Recent data also suggest a possible contribution of Sph1 to UPS modulation
[77]
.  
1.5.2 Synphilin-1 isoforms: Synphilin-1A 
There are more Sph1 isoforms within cells besides the most prominent 919 amino acids 
form
[78]
. However, synphilin-1A (Sph1A) is particularly important, consisting in an unusual Sph1 
splice variant
[74]
. Sph1A is characterized by the absence of Sph1 exons 3 and 4, displaying an extra 
exon (9A) between exons 9 and 10. Curiously, although Sph1A has a start codon different from 
Sph1, the merge of exons 2 with 5 produces a frame shift leading to an identical reading frame for 
both proteins after exon 2. In summary, Sph1A only differs from Sph1 at the N-terminus and at the 
C- terminus (due to exon 9A) (Figure 6)
[74, 79]
.  
 
Figure 6 – Alternative splicing of SNCAIP gene and synphilin-1A structure. Sph1A coding region begins in a start 
codon different from Sph1 and finishes nearly in the middle of exon 10. Thence, Sph1A differs from Sph1 at the N-
terminus and at the C-terminus. Furthermore, Sph1A lacks exons 3 and 4 and displays an extra exon, 9A. Despite the 
alternative splicing, Sph1A is essentially equal to Sph1 in terms of structural domains, also containing the RVTF motif 
(the PPP1 binding domain). Nevertheless, lacks the first and part of the second ankyrin-like repeats. It is suggested that 
Sph1A aggregation properties are in part due to its shorter N-terminus, allowing ankyrin-like repeats to be more 
exposed[74]. (ANK, ankyrin-like repeats; CC, coiled-coil domain; ATP/GTP BM, ATP, GTP-binding domain.)     
Sph1A is an aggregation-prone isoform, being able to spontaneous aggregation in cell 
models even in the absence of proteasomal inhibitors. Nonetheless, the formation of more 
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organized Sph1A inclusion bodies requires proteasomal inhibition. There is limited information 
concerning Sph1A but it is able to interact with Sph1 (possibly through the ankyrin-like domains), 
α-syn and SIAH, recruiting them to its inclusion bodies. Upon recruitment of Sph1 to Sph1A-
containing inclusions, SIAH-mediated degradation of Sph1 decreases, promoting inclusions 
formation within cells. Furthermore, Sph1A is also able to reduce SIAH ubiquitin-ligase activity, 
decreasing SIAH auto-ubiquitylation and ubiquitylation of SIAH substrates. This negative 
modulation performed by Sph1A promotes SIAH substrates accumulation, facilitating protein 
aggregation
[74, 79, 80]
.    
Despite the lack of studies concerning Sph1A, this isoform has reinforced Sph1 relevance for 
LBs formation as it is an aggregation-prone protein potentially able to take part in LBs seeding. 
Thence, Sph1A may be involved in the early events of LBs formation. Nevertheless, Sph1A studies 
display two main limitations: (1) all of them are overexpression based which could be limiting as 
Sph1A has low abundance within cells in comparison with Sph1; and (2) it is not known if all LBs 
contain Sph1A as such studies have not been performed so far
[74, 79, 80]
.   
1.5.3 Synphilin-1 aggregation properties and modulation by Sph1 interactors 
Many studies have documented the ability of Sph1 to form inclusions upon overexpression 
in cell culture models, both alone or with α-syn[53, 81]. This process usually begins with the 
production of multiple small highly mobile aggregates which are dispersed through the cytoplasm. 
Nevertheless, small aggregates can be rapidly translocated into aggresomes if proteasome inhibitors 
are used, being the translocation dependent on Sph1 aggresome-targeting signal
[40, 41]
. Furthermore, 
Sph1 aggregation could be enhanced through K63-linked polyubiquitylation
[82]
.  
After these observations, efforts have been made in order to understand Sph1 aggregation 
patterns and aggresomes formation. Its relevance for PD pathogenesis and LBs formation lies in 
three main ideas: (1) Sph1 is able to produce aggresomes in cell culture models and LBs      
formation is thought to be an aggresome-related process
[42, 43, 53, 81]
; (2) Sph1 is able to interact with 
α-syn and its co-expression greatly enhances aggresomes production[53, 83]; (3) Sph1 appears mainly 
in the central core of LBs
[84]
. In light of this, Sph1 has gathered great attention as it could be related 
with LBs seeding within cells, potentially functioning as a scaffold protein. Obviously, LBs 
formation is perhaps even more complex, being Sph1 just another element. Nevertheless, many of 
its interactors have been discovered (besides α-syn) and they have provided a huge amount of 
information concerning modulation of Sph1-containing aggresomes production. Interestingly, some 
of the most relevant interactors are: (1) E3 ubiquitin-ligases, (2) UPS components and (3) some 
kinases. Furthermore, many of them are also PD-related proteins. 
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Modulation through E3 ubiquitin ligases 
At normal conditions, Sph1 is highly ubiquitylated and degraded by UPS, being its 
ubiquitylation performed by four major E3 ubiquitin ligases: parkin, SIAH-1, SIAH-2 and dorfin
[84-
86]
. However, the ubiquitylation patterns of SIAH and parkin are distinct. Indeed, SIAH attaches 
polyubiquitin chains via lysine 48 (K48) residues which act as a proteasomal targeting signal. On 
the other hand, parkin attaches ubiquitin chains to lysine 63 (K63) residues which is a mechanism 
of signal transduction instead of degradation
[82]
. Ubiquitylation by dorfin is still poorly 
understood
[85]
. Therefore, any UPS dysfunction will lead to the accumulation of SIAH-
ubiquitylated Sph1, eliciting inclusion bodies formation within cells
[87]
. However, also K63 
ubiquitylation is able to produce inclusion bodies
[82]
. Ubiquitylation seems to be important for 
aggregation as a mutant Sph1 unable to be ubiquitylated by SIAH does not form inclusions
[87]
. 
Modulation through UPS components 
Besides ubiquitin ligases, Sph1 also interact with some proteasomal components decreasing 
proteasomal function
[86, 88]
. Among them, the regulatory protein S6-ATPase is particularly 
important, being inhibited by Sph1 when they are co-expressed. This leads to high number of 
inclusion bodies within cells
[77]
. On the other hand, the interaction between Sph1 and NUB1 
decreases the number of Sph1 inclusions as NUB1 accelerates Sph1 degradation by unknown 
mechanism
[89]
.   
Modulation through protein kinases 
Protein reversible phosphorylation is a major post-translational modification known to 
modulate a variety of cellular processes, including ubiquitylation of diverse proteins. Thence, there 
are several protein kinases able to interact with Sph1
[86]
, particularly casein kinase II (CKII)
[90]
 and 
glycogen synthase kinase 3 β (GSK3β)[88, 91]. CKII phosphorylates Sph1 in vivo, increasing Sph1/α-
syn interaction without affecting its ubiquitylation state
[90]
. Thence, the number of inclusion bodies 
increases. On the other hand, GSK3β phosphorylation of Sph1 decreases its ubiquitylation and 
inclusion bodies formation
[88, 91]
.  
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New Sph1-specific interactors and new conclusions 
The yeast two hybrid technique that led to Sph1 discovery has also uncovered some Sph1-
specific interactors that could not be included in the protein classes previously stated. Two 
important ones are periphilin
[92]
 and kalirin-7
[41]
. 
Periphilin is a multifunctional protein involved in many cellular functions in vivo, being 
expressed during embryogenesis and in adult brains. Periphilin was recently associated to PD for 
four main reasons: (1) periphilin interacts and co-localizes with Sph1 within cells; (2) is present in 
LBs; (3) has functional implications in controlling cell death through caspase-3; and (4) a missense 
mutation in periphilin gene was discovered in two PD patients
[92]
. Thence, this study has reinforced 
the relevance of caspase-3 for the Sph1 cellular effects and PD.  
On the other hand, kalirin-7 is a guanine nucleotide exchange factor (GEF) able to modify 
Sph1 aggregation and transport into aggresomes. Indeed, upon co-expression of Sph1 and kalirin-7, 
there is a dramatic increase of Sph1-containing aggresomes formation. Interestingly, this feature 
was not dependent on kalirin-7 GTP-GDP exchange activity as mutant forms of the protein 
conserved the ability to enhance aggresomes production. This observation was further attributed to 
an interaction between kalirin-7 and HDAC6 and to kalirin-7-promoted activation of HDAC6 
deacetylation activity, promoting Sph1 aggregates transport into aggresomes
[41]
. Perhaps the most 
prominent conclusion of this study was the relation between a Sph1-interacting protein and 
HDAC6.  
1.6 LINKING PROTEIN PHOSPHORYLATION AND SYNPHILIN-1 AGGREGATION 
Protein reversible phosphorylation is the best described mechanism involved in activation 
and inactivation of enzymes and modulation of molecular interactions in signaling pathways. In 
eukaryotic cells, reversible phosphorylation usually occurs on the three hydroxyl-containing amino 
acids, serine, threonine and tyrosine. In order to phosphorylate a specific substrate, a phosphate 
group must be transferred from a donor molecule (frequently ATP), reaction which is performed by 
specific enzymes named kinases. On the other hand, phosphatases revert the reaction by removing 
phosphate groups which are eliminated as inorganic phosphates.  
Although kinases and phosphatases work in a regulated syntony, a great dissimilarity exists 
between them in terms of number. Indeed, the human genome encodes for 518 putative protein 
kinases
[93]
, being the phosphatases around 147
[94, 95]
. Nevertheless, it is thought that combinatorial 
formation of phosphatase holoenzymes from a shared catalytic subunit and a large number of 
regulatory subunits guarantees a great level of substrate specificity in vivo. In light of this, great 
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attention has been given to phosphatase-interacting proteins as they regulate phosphatases activity 
(for review see
[96]
).  
1.6.1 Protein phosphatase 1 isoforms and Protein phosphatase 1-interacting proteins 
There are two main families of protein phosphatases: protein tyrosine phosphatases (PTPs) 
and protein serine/threonine phosphatases (PSPs). Among the PSPs, protein phosphatase 1 (PPP1) 
is emphasized as a major and ubiquitously expressed phosphatase in all eukaryotic cells, being able 
to regulate a huge variety of cellular processes
[96-98]
.  
Similarly to other phosphatases, PPP1 exhibits broad substrate specificity in vitro. 
Nevertheless, it is thought that each assembled and functional PPP1 complex displays stringent 
substrate specificity and elicits specific biological responses. The PPP1 holoenzyme consists of a 
catalytic subunit (PPP1c) and a regulatory (R) subunit. PPP1c is a 35-38 kDa protein which exists 
as three isoforms: α (PPP1CA), β/δ (PPP1CB) and γ (PPP1CC) sharing 90% homology. Moreover, 
two PPP1CC splice variants were described (PP1γ1/PPP1CC1 and PP1γ2/PPP1CC2), being 
PPP1CC2 a testis-specific and sperm-enriched isoform
[99]
. Within cells, several mechanisms are 
responsible for regulation of PPP1 activity: reversible phosphorylation of R subunits, dissociation 
of the R and PPP1c subunits, allosteric regulation of R subunits and inducible expression of R 
subunits
[96, 98]
.  
As R subunits modulate PPP1 activity, they were heavily investigated and about 200 of these 
PPP1-interacting proteins (PIPs) have been identified so far
[96, 100]
. Indeed, each PIP may target 
PPP1 for specific subcellular compartments, modulate substrate specificity or serve as substrate, 
influencing PPP1 physiological functions
[96]
. In order to interact with PPP1, PIPs must possess 
critical consensus motifs, being the RVxF-motif the most frequent. The RVxF-motif comprises the 
consensus sequence [KRL]-[KRSTAMVHNQ]-[VI]-[FIMYDP]-[FW], and binds with high affinity 
to a hydrophobic region remote from PPP1 catalytic site (L288-M290-C291)
[101-103]
. Substrate 
binding to PPP1 through RVxF-motifs does not significantly affect PPP1 conformation but 
promotes the occupation of secondary, lower affinity binding sites able to alter PPP1 activity
[101]
. 
Moreover, this motif should be in an exposed and flexible loop in order to interact with PPP1
[101]
. 
Interestingly, the RVxF-motif is rather common among eukaryotic proteins but only a small 
fraction can be classified as PIP.  
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1.6.2 Protein phosphatase 1α interactome and Sph1A 
Among all mammalian tissues, the brain expresses the highest levels of protein kinases and 
phosphatases. Moreover, all PPP1 isoforms are ubiquitously expressed but PPP1CC1 and PPP1CA 
are expressed at higher levels in several brain regions
[99, 104]
. In order to identify the proteins 
expressed in human brain able to interact with PPP1CA a yeast two hybrid was performed, 
resulting in 66 PIPs of which 39 represented novel interactions. Among the novel interactors, 
Sph1A was particularly prominent because 6 positive clones were obtained, uncovering a possible 
functional association between Sph1A and PPP1
[105]
. 
Interestingly, this finding opens several new hypotheses to fill the huge gap that exists 
concerning the modulation of Sph1A aggregation. Indeed, as previously stated, several kinases are 
thought to modulate Sph1 aggregation and even Sph1/α-syn interaction but the phosphatases 
involved in such mechanisms are largely unknown. Moreover, many structural features of Sph1A 
suggest a possible link with PPP1: (1) Sph1A possesses a PPP1 BM (RVTF)
[105]
; (2) Sph1A 
possesses ankyrin-like repeats as other established PPP1-associated proteins (53BP2, TIMAP, 
MYPT1/M110/MBS and ANKRD42/SARP)
[106]
. However, in the previously stated ankyrin-
containing proteins, PPP1 BMs immediately precede the start of the first ankyrin domain, except 
for SARP in which the binding motif partially lies within the first ankyrin repeat
[106]
. This is 
entirely different in Sph1A as the RVTF motif is located C-terminally (residues 449-452), far from 
the ankyrin-repeats (residues 28-123). 
Thence, Sph1A fulfill several criteria to be studied as a putative PIP. Clarifying such protein-
protein interaction could be mutually interesting, providing a new PIP for the growing list of PPP1 
associated proteins, and filling a gap concerning phosphatases able to regulate Sph1 aggregative 
properties and able to play a role in PD pathogenesis.  
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2. Aims 
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PD is a neurodegenerative disorder in which cells develop inclusion bodies termed LBs. 
However, the mechanism behind LBs formation remains poorly understood. Interestingly, Sph1 
and its major splice variant, Sph1A, are two proteins already identified in LBs composition and 
both are suggested to play a role in their formation. Indeed, (1) both are α-syn-interacting 
proteins
[53]
; (2) both are able to produce inclusion bodies resembling LBs, upon overexpression in 
cell models
[53]
; and (3) a Sph1 mutation has been associated to increased susceptibility to develop 
PD
[73]
. Therefore, efforts have been made in order to clarify the regulatory mechanisms behind 
Sph1/Sph1A aggregation because it could be a way to unravel new aspects of LBs formation. 
Nevertheless, a huge gap exists because, although many modulators of Sph1 aggregation are 
known (see Introduction – Section 1.5), no phosphatases able to act on Sph1 and/or Sph1A have 
been properly described until now. In light of this, Sph1A was recently identified as a putative PIP 
in human brain, through yeast two hybrid
[105]
. This putative interaction between Sph1A and PPP1 
must be validated by other means, besides yeast two hybrid, but could represent an important event 
for Sph1A regulation.  
Therefore, the aim of this study is to confirm Sph1A/PPP1 interaction and to clarify the 
role of this complex in inclusion bodies formation. In order to achieve these aims, several tasks 
will be performed: 
a) To evaluate the effect of Sph1A in PPP1CA and PPP1CC targeting and subcellular 
localization, in HEK293 cells overexpressing Sph1A;  
b) To compare the aggregation properties of wild type Sph1A and a Sph1A mutant in which 
the PPP1 BM has been mutated by quantification and morphometric characterization of 
the aggregates formed; 
c) To assess if Sph1A is able to form bona fide aggresomes upon Sph1A overexpression in 
HEK293 cells;  
d) To evaluate if Sph1A/PPP1 interaction modulates Sph1A association with α-syn, 
interfering with α-syn recruitment for Sph1A aggregates.  
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3. Materials and Methods 
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3.1 CELL LINES 
The cell model applied in the present study was human embryonic kidney 293 cells 
(HEK293) with 3 to 20 passages. HEK293 cells were purchased from ATCC and were tested for 
Mycoplasma contamination before performing any experiment. 
3.2 REAGENTS AND ANTIBODIES 
Nocodazole was purchased from Sigma-Aldrich and was reconstituted in DMSO to a final 
concentration of 33.2 mM (stock). Nocodazole stock solution was stored at -20ºC. 
Commercial primary antibodies used in the present work included: (1) mouse anti- γ-tubulin 
monoclonal antibody (Sigma-Aldrich); (2) rabbit anti-α-synuclein polyclonal antibody (Sigma-
Aldrich); and (3) mouse anti-GFP monoclonal antibody (Sigma-Aldrich). Besides commercial 
antibodies, two homemade antibodies were also used: anti-PPP1CA (CBC2C) and anti-PPP1CC 
(CBC3C). Anti-PPP1CA was raised in rabbits against the PPP1CA C-terminal peptide, 
NKGKYGQFSGLNPGG. Anti-PPP1CC was raised in rabbits against the PPP1CC C-terminal 
peptide, KKPNATRPVTPPRGMITKQAKK, and detects PPP1CC1 and PP1CC2. 
Secondary antibodies used included Texas Red anti-mouse (Sigma-Aldrich), Texas Red anti-
rabbit (Sigma-Aldrich), Alexa Fluor 594 anti-mouse (Sigma-Aldrich) and Alexa Fluor 594 anti-
rabbit (Sigma-Aldrich). For detection in Li-Cor’s Odyssey Infrared Imaging System, infrared 
IRDye-labeled anti-rabbit and anti-mouse were applied. 
3.3 PLASMID CONSTRUCTS 
Constructs used in transfection protocols, Sph1A-GFP (WT Sph1A) and Sph1A-RVTA-GFP 
(MT Sph1A), were made by Dr.ª Sara Esteves (for more details on constructs used see Appendix). 
Sph1A-RVTA-GFP is a mutant form of Sph1A-GFP in which the PP1 BM was mutated from 
RVTF to RVTA using the QuickChange Site-Directed Mutagenesis Kit (Stratagene now Agilent 
Technologies). A midi preparation was performed for both constructs using PureYield
TM
 Plasmid 
Midiprep System (Promega, UK), in accordance with the manufacturer’s instructions (Sph1A-GFP: 
268 ng/µL, ratio 1.89; Sph1A-RVTA-GFP: 304 ng/µL, ratio 1.89). Constructs were ethanol 
precipitated to achieve approximately 1 µg/µL of concentration. 
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3.4 CELL THAWING 
Human embryonic kidney 293 (HEK293) cryopreserved cells (with 3 passages) were 
removed from the liquid nitrogen store and placed into a 37ºC water bath. The 1 mL vial was 
gently swirled in the 37ºC water bath for 2 minutes and transferred to a laminar flow hood, after 
vial decontamination with 70% ethanol. Then, thawed cells were transferred to a centrifuge tube 
and the cell suspension was centrifuged at 200 x g for 5 minutes. Finally, the supernatant was 
discarded, the pellet was resuspended in 1 mL of pre-warmed complete medium and the cell 
suspension was gently transferred drop by drop to a 60 mm culture dish with 9 mL of pre-warmed 
complete medium. The medium was changed after 6 hours.        
3.5 CELL COUNTING WITH TRYPAN BLUE 
In order to equalize cell number across transfection experiments, HEK293 cells were 
counted using Trypan Blue (Sigma-Aldrich). Briefly, 10 µL of 0,4% Trypan Blue were mix with 
90 µL of cell suspension and viable (unstained) cells were counted using a Haemocytometer. 
3.6 CELL MAINTENANCE 
HEK293 cells were maintained with Dulbecco’s Modified Eagle’s Medium (DMEM) – high 
glucose with L-glutamine (D5648-1L, Sigma), supplemented with 10% (v/v) fetal bovine serum 
(FBS, Gibco), 100 U/mL penicillin/100 mg/mL streptomycin (p/s) and 3,7 g/L NaHCO3 at 37ºC 
and 5% CO2.    
3.7 TRANSFECTION WITH TURBOFECT TRANSFECTION REAGENT 
Cells were transfected in 6 well plates using TurboFect reagent (Roche), according to the 
manufacturer’s instructions. Briefly, the culture medium was replaced with serum- and 
antibiotic/antimycotic-free DMEM. Then, 2 µg of DNA were diluted in 100 µL of serum- and 
antibiotic/antimycotic-free DMEM and 4 µL of TurboFect reagent were added to each tube. After 
gentle bubbling with the pipette, the mixtures were allowed to rest for 25 minutes at room 
temperature. Finally, the complexes were added into the cell medium, drop by drop with gentle 
rocking of the plate. The cells were incubated at 37ºC with 5% CO2 for 24 hours/48 hours and the 
medium replaced after the first 5 hours of incubation. 
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3.8 NOCODAZOLE TREATMENT 
Nocodazole treatment was started 24 hours after transfection, was performed for 6 hours and 
the inhibitor concentration was kept at 5 µM. 
3.9 IMMUNOCYTOCHEMISTRY 
Before seeding cells, an 18 mm coverslip was introduced in each well of a 6 well plate. Poly-
L-ornithine (Sigma-Aldrich), 0.1 mg/mL, was added to each well for 5 minutes. At that point, poly-
L-ornithine was removed and two washing steps were performed with autoclaved water. Wells and 
coverslips were left to dry before use. 
After surface activation, HEK293 cells were cultured in pre-coated glass coverslips and 
transfected as described above. Immunocytochemistry was performed at two time points: 24 hours 
and 48 hours. Each well was washed two times with 1X PBS and a 4% paraformaldehyde fixative 
solution was added and left to stand for 30 minutes. Then, cells were washed three times with 1X 
PBS. For permeabilization, a 0,2% TRITON X-100 solution was added for 10 minutes, followed by 
3 washes with 1X PBS. Blocking was carried out for 30 minutes with PBS/3% BSA. After 
blocking, the primary antibody diluted in PBS/3% BSA was added and incubated at room 
temperature for 1hour and 30 minutes to 2 hours, depending on the antibody used. After three 
washes with 1X PBS, the appropriate secondary antibody was added using the same methodology 
and incubated for 1 hour. Finally, three washes were performed and coverslips were stained using 
50 µL of Hoechst (PolyScience) staining for 4 minutes. For mounting onto microscope glass slides, 
a 3Mowiol:1n-propyl-galate (ROTH) solution was used.  
3.10 IMAGE ACQUISITION AND AGGREGATES COUNTING 
Epifluorescence microphotographies were acquired with an Olympus IX-81 inverted 
epifluorescence microscope, equipped with EGFP (Chroma 41020) and Texas Red (Chroma 
41004) filter cubes for fluorophore microscopy visualization. Cells were blindly counted in 
randomly chosen fields to have more than 50 aggregate-containing cells in each coverslip.  
3.11 STATISTICAL ANALYSIS 
In the present study, several experiments required aggregates counting: (1) quantification of 
cells bearing aggregates after transfection with WT Sph1A and MT Sph1A; (2) quantification of 
cells bearing aggregates with predefined sizes, after transfection with WT Sph1A and MT Sph1A; 
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and (3) quantification of transfected cells bearing aggregates with predefined sizes, after 
Nocodazole treatment in comparison with untreated conditions. In all cases, at least three 
independent experiments (replicas) were performed for each condition to assure reproducibility of 
the results. It is worthy to note that all these experiments were based in the quantification of 
specific, categorical events (e.g. having aggregates vs. not having aggregates; having small 
aggregates vs. having big aggregates) which produce categorical data. Therefore, statistical analysis 
was adjusted to this type of results.   
For a more general analysis, quantitative data from aggregates counting were expressed as 
arithmetic mean ± standard deviation (SD) based on the three replicas performed for each 
condition. Then, means were compared and the overlap between standard deviations was used to 
address the significance of the differences identified. 
However, a more detailed analysis was also performed using statistical tests but to compare 
corresponding replicas within the same experiment. That means that, for each experiment, control 
replica 1 was compared with treatment replica 1 and so on, as if they were paired samples. Then, 
contingence tables were produced and p-values were calculated using Pearson’s chi-squared test 
and Cochran-Mantel-Haenzel chi-squared test. These tests evaluate if there is an association 
between a specific treatment and a specific effect produced and are suitable to apply in cases of 
categorical data. 
3.12 CELL COLLECTION AND SAMPLE FRACTIONATION 
Transfected HEK293 cells were collected, lysed and subjected to fractionation in order to 
separate triton-soluble components from triton-insoluble components. Briefly, transfected HEK293 
cells (plated in 60 mm dishes, 6.0x10
5
 cells/dish) were washed 2 times with cold PBS 1X and 
harvested by scrapping in 200 µL of non-denaturating cold lysis buffer containing 1% TRITON X-
100 (50 mM Tris-HCl, pH 7.5; 175 mM NaCl; 5 mM EDTA; 1% TRITON X-100; protease and 
phosphatase inhibitors mix). Then, cell suspensions were ice incubated for 30 minutes. In order to 
pellet triton-insoluble components, cell suspensions were centrifuged at 16000 x g for 30 minutes 
(4ºC). Finally, the supernatants were transferred to new microtubes (and labeled as Triton-soluble 
fractions) while pellets were resuspended in 200 µL of 2% SDS-containing buffer (similar to lysis 
buffer but containing 2% SDS instead of TRITON) and sonicated for 10 seconds (being labeled as 
Triton-insoluble fractions). 
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3.13 BCA PROTEIN ASSAY 
The protein content of HEK293 lysates was determined using BCA protein assay (Pierce). 
Reactions were performed by addition of 200 µL of Working Reagent to 25 µL of each sample and 
the standards were prepared as described in the appendix. Both standards and samples were 
incubated at 37ºC for 30 minutes. The absorbances were then measured at 562 nm and a standard 
curve was constructed by plotting the absorbance value of each BSA standard against its 
concentration. The standard curve allowed the estimation of the protein concentration of each 
sample from its absorbance value. 
3.14 SDS-PAGE AND IMMUNOBLOTTING 
Samples were subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). For that, 
50 µg of each sample were mixed with 4x loading buffer and resolved on a 15% polyacrylamide 
gel. Gels were run at 200 volts for approximately 1 hour.  
After electrophoresis, proteins were transferred to nitrocellulose membranes at 200 
miliampers for approximately 1 hour and 30 minutes. Membranes blocking was carried out by 
immersion in 5% non-fat milk/1X TBST, for 1 hour with shaking. Blocked membranes were then 
washed 3 times with 1X TBST and incubated with primary antibody diluted in 3% non-fat milk/1X 
TBST solution, for 2 hours with shaking. The 3 washing steps were repeated with 1X TBST and 
membranes were incubated with the appropriate secondary antibody also diluted in 3% non-fat 
milk/1X TBST solution, for 1hour with shaking. Bands detection was performed at 700 nm (anti-
rabbit) or 800 nm (anti-mouse) using Odyssey CLx as secondary antibodies were conjugated with 
infrared fluorescent reporters.        
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4. Results 
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4.1 PPP1CA AND PPP1CC ARE TARGETED TO INCLUSION BODIES BY SPH1A AND 
THEIR TARGETING IS DEPENDENT ON SPH1A RVTF MOTIF    
As Sph1A was found to interact with PPP1CA by an yeast two hybrid screen of a human 
brain library, it was important to validate this interaction by other methodologies
[105]
. Some 
previous results from our laboratory have already demonstrated the existence of a conserved PPP1 
BM (RVTF) in Sph1A amino acid sequence. Also, Sph1A/PPP1 interaction was previously 
validated using yeast co-transformation and overlay blot assay
[107]
. Thence, in the present work, 
Sph1A/PPP1 interaction is addressed through immunofluorescence studies in HEK293 cells. 
In order to evaluate Sph1A/PPP1 co-localization and its specificity, HEK293 cells were 
transfected with WT Sph1A and MT Sph1A. The first construct corresponds to wild type Sph1A 
fused with GFP. The second is a Sph1A mutant, in which the PPP1 BM (RVTF) was disrupted by 
mutagenesis of the phenylalanine residue to adenine, originating the motif RVTA that does not 
bind PPP1
[107]
. After 48 hours of transfection, endogenous PPP1CA and PPP1CC were stained with 
specific antibodies and the subcellular localization of Sph1A and the two PPP1 isoforms were 
compared (Figures 7 and 8).   
Upon WT Sph1A overexpression in HEK293 cells, transfected cells develop a diffuse green 
signal across the cytoplasm, corresponding to soluble, GFP-tagged WT Sph1A. Furthermore, some, 
but not all, of the transfected cells also display GFP-positive aggregates with an exclusive 
cytoplasmic distribution (Figure 7). These aggregates may be isolated (Figure 7A) or may be 
multiple and dispersed across the cytoplasm (Figures 7B). When HEK293 cells overexpressing WT 
Sph1A are stained with PPP1CA and PPP1CC specific antibodies, both endogenous PPP1CA and 
PPP1CC reveal nuclear and cytoplasmic distribution, which is in accordance with previous studies 
(Figure 7)
[108]
. Actually, both PPP1CA and PPP1CC are known to be present in the cytoplasm and 
nucleus of mammalian cells but while nuclear PPP1CA mainly occurs in a diffuse nuclear pool, 
nuclear PPP1CC accumulates predominantly within the nucleolus
[108]
. Although Sph1A and the two 
PPP1 isoforms maintain their expected subcellular localization, according to literature
[74, 108]
, in 
aggregate-containing cells, a marked co-localization between both PPP1CA (Figure 7A) and 
PPP1CC (Figure 7B) and WT Sph1A inclusions can be detected. Therefore, WT Sph1A seems to 
interact with PPP1CA and PPP1CC, recruiting them to the cytoplasmic inclusions formed. 
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Figure 7 - Wild type synphilin-1A co-localizes with endogenous PPP1CA and PPP1CC in cytoplasmic inclusion 
bodies. A: Fluorescence microscopy visualization and intracellular localization of the Sph1A-GFP fusion protein (WT 
Sph1A-GFP) and endogenous PPP1CA (Anti-PPP1CA) within HEK293 cells overexpressing wild type synphilin-1A. B: 
Fluorescence microscopy visualization and intracellular localization of the Sph1A-GFP fusion protein (WT Sph1A-GFP) 
and endogenous PPP1CC (Anti-PPP1CC) within HEK293 cells overexpressing wild type synphilin-1A. Both panels 
display cells with and without aggregates. Cells transfected with EGFP-N1 served as negative control being not able to 
form cytoplasmic aggregates (data not shown). Scale bars: 20 µm. 
Although PPP1CA and PPP1CC co-localize with WT Sph1A in cytoplasmic inclusions, this 
co-localization could represent an unspecific aggregative process, in which cytoplasmic PPP1 is 
A 
B 
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simply sequestered, along with many other inclusion body-related proteins. On the other hand, 
PPP1 could be specifically recruited by Sph1A. Many PIPs are known to modulate PPP1 targeting, 
specifically recruiting PPP1 isoforms to specific subcellular compartments
[96]
. A common feature 
among PIPs is that PPP1 targeting requires a conserved PPP1 BM contained in the PIP primary 
structure
[96]
. These motifs are easily found through in silico studies and Sph1A contains a 
conserved RVTF motif. Nevertheless, many proteins possess PPP1 BM but are not able to 
participate in PPP1 targeting and modulation, not being real PIPs. In light of that, it was necessary 
to address if Sph1A/PPP1 co-localization (Figure 7) is dependent on the Sph1A RVTF motif, or if 
is an unspecific sequestering process. This was achieved through mutation of the RVTF motif to 
RVTA in Sph1A, as described above. 
When HEK293 cells are transfected with the Sph1A-RVTA-GFP construct instead the non-
mutated construct (Sph1A-GFP), no major changes can be seen in MT Sph1A, PPP1CA and 
PPP1CC subcellular localization (Figure 8). Indeed, Sph1A forms a cytoplasmic, soluble pool and 
some cytoplasmic aggregates in transfected cells while endogenous PPP1CA and PPP1CC remain 
in the cytoplasm and nucleus, as expected (Figure 8). Moreover, not all transfected cells develop 
Sph1A inclusions and the inclusions formed can be isolated or multiple (Figure 8). However, there 
is a striking decrease in Sph1A/PPP1 co-localization within inclusion bodies for both PPP1 
isoforms (Figure 8A and 8B), independently of aggregates morphology and size. Therefore, a 
unique point mutation in the Sph1A RVTF motif is sufficient to abolish PPP1CA and PPP1CC 
recruitment for Sph1A inclusion bodies.  
Taken together, these findings confirm Sph1A/PPP1 interaction for two PPP1 isoforms 
(PPP1CA and PPP1CC), in ex vivo conditions. Indeed, PPP1CA and PPP1CC are recruited to 
Sph1A cytoplasmic inclusions, independently of the morphology and size of the aggregates. 
Nevertheless, this interaction is specific as requires a conserved PPP1 BM contained in Sph1A 
structure (RVTF). A single point mutation in this motif is sufficient to interrupt PPP1 recruitment 
to inclusion bodies and this effect is also independent of the morphology and size of the inclusions. 
Hence, Sph1A displays many features of a common PIP as it contains a conserved PPP1 BM, it is 
able to interact and target PPP1 isoforms to a specific subcellular compartment (inclusion bodies) 
and this targeting specifically depends on the conserved RVTF motif. Interestingly, as PPP1 is 
targeted to Sph1A inclusion bodies with different morphologies and sizes, PPP1 recruitment might 
be an early event in Sph1A inclusions formation. 
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Figure 8 - Mutant synphilin-1A, in which the RVTF motif is mutated to RVTA, shows decreased co-localization 
with endogenous PPP1CA and PPP1CC in cytoplasmic inclusion bodies. A: Fluorescence microscopy visualization 
and intracellular localization of the mutant Sph1A-GFP fusion protein (MT Sph1A-GFP) and endogenous PPP1CA 
(Anti-PPP1CA) within HEK293 cells overexpressing the synphilin-1A mutant. B: Fluorescence microscopy visualization 
and intracellular localization of the mutant Sph1A-GFP fusion protein (MT Sph1A-GFP) and endogenous PPP1CC 
(Anti-PPP1CC) within HEK293 cells overexpressing the synphilin-1A mutant. Cells with and without aggregates are 
shown. Cells transfected with EGFP-N1 served as negative control being not able to form cytoplasmic aggregates (data 
not shown). Scale bars: 20 µm. 
  
A 
B 
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4.2 DISRUPTION OF SPH1A/PPP1 INTERACTION FAVORS THE FORMATION OF BIG 
AGGREGATES AND ACCELERATES SPH1A AGGREGATION IN HEK293 CELLS 
In the previous section, data suggest that Sph1A could be a novel, putative PIP, specifically 
targeting PPP1CA and PPP1CC to Sph1A cytoplasmic inclusions. Nevertheless, PIPs could have 
other functions besides PPP1 targeting for subcellular compartments, such as modulation of PPP1 
substrate specificity or may serve as PPP1 substrates
[96]
. Therefore, the actual Sph1A role as PIP 
and the functional significance of PPP1 recruitment for inclusion bodies should be clarified.  
In terms of Sph1A role as putative PIP, it is clear that Sph1A is able to specifically target 
PPP1 to inclusion bodies. However, the consequences of such targeting may be quite diverse. 
Indeed, PPP1 could be recruited in order to dephosphorylate Sph1A itself, in which case Sph1A 
will be also a substrate. Nevertheless, Sph1A could also modulate PPP1 substrate specificity, in 
which case PPP1 will be recruited for dephosphorylation of other inclusion body-related proteins. 
Whatever the actual consequence(s) of Sph1A/PPP1 interaction and PPP1 recruitment for inclusion 
bodies, it is likely that it may affect the process of inclusions formation. 
Actually, it is not the first time in which Sph1 phosphorylation state is referred as having a 
modulatory activity on Sph1 aggregation. Indeed, previous studies have suggested that Sph1 
phosphorylation by GSK3β regulates its ubiquitylation and proteasomal degradation, while 
phosphorylation by CKII regulates its interaction with α-syn[88, 90]. Thence, Sph1 phosphorylation 
state could be important to regulate Sph1 degradation or interaction with other inclusion body-
related proteins. In both cases, Sph1 aggregation pattern is altered. Despite that information, there 
are no data available concerning Sph1A and the phosphatases implicated in these mechanisms are 
unclear. 
In light of that, it seems legit to ask whether blockage of PPP1 targeting to Sph1A aggregates 
has any functional consequence, altering (or not) Sph1A aggregation pattern and inclusion bodies 
formation. In order to answer this question, HEK293 cells were transfected with Sph1A-GFP and 
Sph1A-RVTA-GFP, the previously described Sph1A mutant with a mutated PPP1 BM. After that, 
immunocytochemical experiments were performed and both conditions (WT Sph1A and MT 
Sph1A) were compared in terms of percentage of cells bearing aggregates (Figure 9)
[83]
 and in 
terms of morphometric features (number, size and distribution) of these aggregates 
[40, 41]
. To gather 
more details on the aggregation patterns of WT Sph1A and MT Sph1A, aggregate counting and 
morphometric analysis were performed at two different time points: 24 hours and 48 hours, after 
transfection. 
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Figure 9 - Mutation of the Sph1A PPP1 BM RVTF does not significantly change the percentage of HEK293 cells 
bearing inclusions. The graph shows the average number of transfected HEK293 cells containing inclusions when 
transfected with wild type Sph1A (WT) and mutant Sph1A (MT), determined by fluorescence microscopic visualization 
at two time points: 24 (24) and 48 hours (48), after transfection. HEK293 cells transfected with empty EGFP-N1 vector 
(CT GFP) were used as negative control and do not show inclusion bodies. All data represent the mean ± SD of at least 
three independent experiments (n = 300 cells per condition). When Pearson’s chi-squared test and Cochran-Mantel-
Haenszel chi-squared test are applied to compare the proportion of cells with inclusions in corresponding replicas (WT 24 
vs. MT 24 and WT 48 vs. MT 48), no differences can be detected at a significance level of 5% (p-values >0,05). 
Therefore, there is no association between the percentage of cells with inclusions and the type of protein (WT vs. MT) 
used in transfection.  
The percentage of cells with inclusions is used in the present study as a broad measure of the 
aggregative properties of both WT Sph1A and MT Sph1A. Twenty-four hours after transfection, 
nearly 30% of HEK293 cells show cytoplasmic Sph1A inclusion (Figure 9). Forty-eight hours after 
transfection, this number increases to nearly 36% but this rise is not statistically significant (Figure 
9). Furthermore, mutation of the Sph1A PPP1 BM does not significantly alter the percentage of 
cells bearing inclusions, for any studied time point (24 and 48 hours) (Figure 9). Therefore, when 
the aggregative properties of WT Sph1A and MT Sph1A are compared in terms of percentage of 
cells bearing aggregates, they are not significantly different (Figure 9). Interestingly, inclusions are 
formed in the absence of any treatment for proteasome inhibition and with expression of Sph1A 
alone, which is in accordance with previous studies postulating Sph1A aggregation-prone 
properties
[74]
. Furthermore, the percentage of cells bearing inclusions for WT Sph1A 
overexpression (nearly 30%) also matches with previous observations
[74]
.       
Broad quantification of cells displaying aggregates was not able to reveal any functional 
consequence of blocking PPP1 recruitment for inclusion bodies. Thence, a more detailed 
morphometric analysis was performed (Figure 10) based on aggregates size and number, in 
accordance with the following criteria: (1) aggregates with 1 µm or less in diameter were classified 
as small aggregates; (2) aggregates with more than 1 µm to 3 µm in diameter were classified as 
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medium aggregates; (3) aggregates with more than 3 µm in diameter were classified as big 
aggregates; (4) cells bearing multiple small aggregates and just one small aggregate were 
separately counted; and (5) in cells bearing multiple aggregates with different size, just the bigger 
was considered for classification purposes. The 5
th
 criterion was established in order to emphasize 
the dynamics of protein aggregation. Therefore, and as an example, if a given cell contain a 
medium aggregate mixed with multiple small inclusions, it should be sorted in class 2 (medium 
aggregates) because, in terms of aggregation process, it reached the second stage, in which small 
aggregates begin to assemble to form the medium ones. 
 
Figure 10 - Mutation of the Sph1A PPP1 BM RVTF favors the formation of medium and big aggregates in 
HEK293 cells. The graph shows the average number of transfected HEK293 cells displaying small multiple (]0,1] 
multiple), small isolated (]0,1] isolated), medium (]1,3]) and big aggregates (]3,5[), when transfected with wild type 
Sph1A (WT) and mutant Sph1A (MT) for 24 (24) and 48 (48) hours, determined by fluorescence microscopic 
visualization. All data represent the mean ± SD of at least three independent experiments (n = 150 cells per condition). 
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When Pearson’s chi-squared test is applied to compare the aggregation pattern of corresponding replicas (WT 24 vs. MT 
24 and WT 48 vs. MT 48), the differences are statistically significant which means that there is an association between 
the transfected protein (WT Sph1A or MT Sph1A) and the aggregation pattern produced, for both time points at a 
significance level of 5% (p-values <0,05).   
According to the morphometric analysis, 24 hours after transfection with WT Sph1A, the 
majority of the transfected HEK293 cells develops small multiple (48.3%) and small isolated 
inclusions (36.3%) (Figure 10). Contrarily, only 15.5% develop medium and big aggregates (Figure 
10). Interestingly, when the post-transfection period is extended from 24 hours to 48 hours, this 
propensity is maintained as small multiple aggregates continue to dominate the pool of inclusions 
displayed by transfected cells. However, a marked decrease in the number of cells bearing small 
isolated inclusions occurs, while the number of cells containing medium and, most significantly, 
big aggregates increases (Figure 10). Therefore, WT Sph1A has a clear propensity to form small 
(multiple and isolated) aggregates within HEK293 cells, both 24 and 48 hours after transfection. 
Moreover, as the post-transfection period is extended, there is an increase in the number of cells 
containing medium and big aggregates, which certainly reflects a process of assembly of small 
aggregates to form the bigger ones, as is described in literature
[40, 41]
.  
On the other hand, 24 hours after transfection, cells overexpressing MT Sph1A develop 
small, medium and big inclusions nearly in the same proportion (Figure 10). Furthermore, the 
proportion of cells containing big aggregates is extremely high upon transfection with the mutant 
form of Sph1A in comparison to cells transfected with the wild type protein, for both time points 
studied (Figure 10). Additionally, when the post-transfection period is extended from 24 hours to 
48 hours, a marked decrease in small isolated and medium aggregates occurs, while a huge increase 
in big aggregates can be observed (Figure 10). Thence, MT Sph1A displays a clear propensity to 
form big aggregates. Moreover, comparing the two time points for MT Sph1A, a decrease in the 
proportion of cells containing small isolated and medium aggregates can be observed, 
concomitantly with an increase in the proportion of cells containing big inclusions. Then again, 
these differences between time points may be due to the assembly of small aggregates to form 
bigger ones as the post-transfection period is increased.  
All together, these data suggest that, upon mutation of the Sph1A PPP1 BM, Sph1A suffers 
an alteration of its aggregation pattern, in which the formation of big aggregates is favored (Figure 
10). Furthermore, the disruption of Sph1A/PPP1 interaction also seems to accelerate the process of 
inclusion bodies formation as the more advanced inclusion types (big aggregates) are massively 
produced earlier. Thence, blocking PPP1 targeting to inclusion bodies seems to enhance Sph1A 
aggregative properties and accelerate the conversion of small aggregates in big aggregates, as well 
as aggregates assembling and growing mechanisms. 
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4.3 WT SPH1A AND MT SPH1A DO NOT PRODUCE BONA FIDE AGGRESOMES UPON 
OVEREXPRESSION IN HEK293 CELLS WITHOUT ANY TREATMENT 
According to data described in section 4.2, WT Sph1A and MT Sph1A are able to form 
cytoplasmic aggregates but display different aggregation patterns. Interestingly, some of the 
medium and big aggregates formed within HEK293 cells overexpressing Sph1A seem to have 
certain similarities with aggresomes. Indeed, these bigger Sph1A inclusions (1) seem to have 
perinuclear localization, (2) increase in proportion as the post-transfection periods are extended 
from 24 hours to 48 hours (suggesting assembling of small cytoplasmic aggregates to form bigger 
inclusions, perhaps true aggresomes) (Figure 10) and (3) some cells display small multiple 
aggregates aligned as if they are associated with microtubules (Figure 11). All together, these cues 
have raised the hypothesis of some of these Sph1A inclusions be bona fide aggresomes.    
 
Figure 11 –HEK293 cell transfected with WT Sph1A displaying aligned small multiple aggregates, suggesting a 
putative association with the microtubules network. Scale bar: 20 µm. Right image emphasizes the presence of 
dispersed GFP-positive aggregates which are also present together with the aligned inclusions. Right image is not at 
scale. 
Currently, there are no studies addressing if the inclusions formed by Sph1A are bona fide 
aggresomes. However, the ability of Sph1 to form aggresomes within transfected cells is well 
established in literature, although requires cell treatment with proteasome inhibitors. As no 
proteasome inhibitors were used in the present work and giving the cues described above, it is 
interesting to address if any Sph1A inclusions produced upon Sph1A overexpression in HEK293 
cells are true aggresomes. 
Two main criteria allow inclusions classification as aggresomes: (1) the dependence on 
microtubules for their formation; and (2) localization at the MTOC. Both these criteria were 
assessed. 
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In order to assess if microtubules are required for the formation of Sph1A bigger aggregates, 
HEK293 cells transfected with Sph1A-GFP and Sph1A-RVTA-GFP were treated with Nocodazole, 
as described (see Materials and Methods), for microtubule polymerization blocking. Then, the 
morphometric analysis of Sph1A aggregates was performed again, for evaluation of WT Sph1A 
and MT Sph1A aggregation patterns under conditions of microtubule polymerization blocking. 
This morphometric analysis was performed through immunofluorescence experiments (Figure 12). 
If Sph1A big aggregates are, indeed, aggresomes, upon Nocodazole treatment it is expected a 
decrease in the proportion of cells displaying big aggregates and an increase in the proportion of 
cells containing small aggregates.  
 
Figure 12 – HEK293 cells overexpressing WT Sph1A and MT Sph1A do not display significant sensitiveness to 
Nocodazole treatment. The graphs show the average number of transfected HEK293 cells displaying small multiple 
(]0,1] multiple), small isolated (]0,1] isolated), medium (]1,3]) and big aggregates (]3,5[), when transfected with wild 
type Sph1A or mutant Sph1A for 24 hours, in the absence of any treatment (WT 24 and MT 24)) and upon treatment with 
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Nocodazole (WT Nocodazole and MT Nocodazole). Transfected HEK293 cells treated with DMSO (WT DMSO and MT 
DMSO) were used as negative control. All data represent the mean ± SD of at least three independent experiments (n = 
150 cells per condition). When Pearson’s chi-squared test is applied to compare the aggregation pattern of corresponding 
replicas (WT 24 vs. WT Nocodazole; WT 24 vs. WT DMSO; MT 24 vs. MT Nocodazole and MT 24 vs. MT DMSO), 
there are statistically significant differences in the aggregation pattern of MT Sph1A after treatment with Nocodazole and 
also with DMSO, in comparison with the non-treated control. Therefore, in cells transfected with MT Sph1A the 
aggregation pattern is significantly altered by Nocodazole and by DMSO, at significance level of 5% (p-values <0,05). 
Contrarily, Nocodazole does not produce significant differences in the aggregation pattern of WT Sph1A at a significance 
level of 5% (p-values >0,05).  
As described in section 4.2 (Figure 10), WT Sph1A produces mainly small cytoplasmic 
aggregates (multiple and isolated) under untreated conditions. Upon treatment with Nocodazole, 
this tendency does not change and the different types of aggregates continue to be formed nearly in 
same proportion in WT Sph1A transfected cells (Figure 12). 
On the other hand, HEK293 cells overexpressing MT Sph1A display nearly the same 
proportion of the 4 classes of aggregates under untreated conditions (Figure 12). Interestingly, 
when incubated with Nocodazole (5 µM), a slight change in MT Sph1A aggregation pattern seems 
to occur, with a slight increase in the proportion of small aggregates and a decrease in the number 
of cells bearing medium and big aggregates (Figure 12). The interpretation of these differences 
promoted by Nocodazole becomes even more difficult as all effects seen under Nocodazole 
treatment also occur in the negative control, in which MT Sph1A transfected HEK293 cells were 
treated with DMSO alone (Nocodazole’s solvent) (Figure 12). 
Taken together, these results do not allow the clear classification of Sph1A inclusion bodies 
documented in the present work as aggresomes. Actually, in cells overexpressing WT Sph1A, 
treatment with Nocodazole does not produce any visible change in Sph1A aggregation. On the 
other hand, cells overexpressing MT Sph1A form more small aggregates and less medium and big 
aggregates when treated with Nocodazole, matching the expected results if some of the MT Sph1A 
aggregates were real aggresomes. However, as DMSO alone (negative control) is able to produce 
the same effect, these results are inconclusive for MT Sph1A. The manipulation produces the 
desired effect but could not be attributed specifically to Nocodazole.    
Although Nocodazole treatment produced inconclusive results, the classification of inclusion 
bodies as aggresomes also requires their co-localization with MTOC markers, as stated above. 
Thence, HEK293 cells transfected with Sph1A-GFP and Sph1A-RVTA-GFP were also stained 
with anti-γ-tubulin monoclonal antibody, as γ-tubulin is a well known MTOC marker.    
In non-transfected HEK293 cells, γ-tubulin is clearly enriched near the nucleus, co-localizing 
with two perinuclear, large dots, corresponding to the centrosome (Figure 13). Furthermore, in 
some non-transfected cells, these two large, perinuclear dots appear in opposite poles, suggesting 
mitosis occurrence, in which cases also the mitotic fuse can be distinguished. Nevertheless, the 
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images taken also display some background, which turns more difficult the clear identification of 
the centrosome in all cells. This background problem could not be solved even after a prolonged 
optimization period, in which many dilutions were tested for both the primary and secondary 
antibodies.  
 
Figure 13 - Non-transfected HEK293 cells stained with anti-γ-tubulin antibody display centrosomes at the 
perinuclear space. Scale bar: 20 µm. 
Contrarily to non-transfected cells, which display a visible centrosome at the perinuclear 
space, in cells transfected with WT Sph1A and MT Sph1A and containing aggregates the two 
large, perinuclear dots could not be clearly distinguished, for the majority of cells present in each 
coverslip (Figure 14). Indeed, centrosome identification is sporadically possible but not in a 
consistent way to be significant or conclusive (Figure 14). Furthermore, in some of these cells in 
which the centrosome is identified, some degree of co-localization with big Sph1A aggregates is 
found, but is also a sporadic event (Figure 14). It is possible that the punctuate background signal 
produced some degree of confounding, does not allowing an unequivocal centrosome observation 
for the majority of transfected cells. Nevertheless, an astonishing event is the clear identification of 
centrosomes in a great number of non-transfected cells and in cells not bearing aggregates, 
localized around the transfected ones in the same coverslip.  
In light of that, for classification purposes as aggresomes, the γ-tubulin experiment is also 
inconclusive. Actually, some transfected cells (for both Sph1A constructs) display co-localization 
between big aggregates and the centrosome but in an inconsistent and sporadic way, insufficient to 
be considered clearly significant. Nevertheless, the clear identification of centrosomes in non-
transfected cells contrarily to the transfected ones is a curious event. It is unclear whether this is 
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caused by confounding due to high background, transfection artifacts or some true cellular event 
related with protein aggregation or even apoptosis. The clarification of this topic requires further 
evaluation.   
 
Figure 14 – Evaluation of aggresomes formation by transfected HEK293 cells through co-localization between 
inclusion bodies and the MTOC. A: Fluorescence microscopy visualization of Sph1A inclusion bodies (WT Sph1A-
GFP) and the MTOC (Anti-γ-tubulin) in cells overexpressing WT Sph1A. One transfected cell clearly displays a 
perinuclear bigger aggregate co-localizing with the centrosome. Two non-transfected cells also show perinuclear dots 
corresponding to the MTOC. B: Fluorescence microscopy visualization of Sph1A inclusion bodies (MT Sph1A-GFP) and 
A 
B 
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the MTOC (Anti-γ-tubulin) in cells transfected with MT Sph1A. At the center of the figure, one transfected cell shows a 
big perinuclear aggregate co-localizing with the MTOC. Two other cells contain visible centrosomes but are non-
transfected. Scale bars: 20 µm. White arrows indicate centrosome localization. 
Taken together, Nocodazole treatment and γ-tubulin staining fail to demonstrate the true 
nature of Sph1A inclusion bodies as aggresomes. Thence, the aggregation patterns described in the 
previous section for WT Sph1A and MT Sph1A seem to be mainly due to passive events rather 
than active events mediated by the cytoskeleton. However, cytoskeleton intervention could not be 
completely excluded as Nocodazole produced a slight effect and aggregates co-localized with 
MTOC in some residual cells. Furthermore, no proteasome inhibitors were used in the present 
work.            
4.4 COMPARISON BETWEEN TRITON-SOLUBLE FRACTIONS AND TRITON-INSOLUBLE 
FRACTIONS OF HEK293 CELLS TRANSFECTED WITH WT SPH1A AND MT SPH1A – 
A PRELIMINARY STUDY 
The final aim of the present work was to address if Sph1A/PPP1 interaction was able to 
modulate Sph1A/α-syn interaction, affecting α-syn recruitment to inclusion bodies. This question 
came from the idea that Sph1A and/or α-syn phosphorylation state could modulate Sph1A/α-syn 
interaction. In order to answer this question, HEK293 cells transfected with WT Sph1A and MT 
Sph1A were subjected to fractionation using triton-containing lysis buffer and PPP1CA and α-syn 
recruitment to the triton-insoluble fractions were compared in both cases.  
Although this is a preliminary work, needing further replication and quantification, the 
results were interesting. Indeed, when transfected cells (with WT Sph1A and MT Sph1A) are 
fractionated using 1% TRITON X-100, Sph1A (75 kDa) appears both in the triton-soluble and 
triton-insoluble fractions for both constructs used (Figure 15). Furthermore, more bands can be 
seen in soluble fractions besides the 75 kDa band, although it is unclear if they are unspecific or 
by-products of GFP-tagged Sph1A. As expected, GFP-tagged Sph1A is absent in negative controls 
(non-transfected cells) (Figure 15). Thence, upon overexpression in HEK293 cells, both WT 
Sph1A and MT Sph1A exist in soluble form and in a triton-insoluble form, certainly corresponding 
to aggregated Sph1A, confirming the previous results of this work.  
In terms of PPP1CA, this phosphatase can be detected both in the triton-soluble and triton-
insoluble fractions after fractionation of non-transfected HEK293 cells, but it is more abundant in 
the soluble fraction in control conditions (Figure 15). Therefore, PPP1CA naturally occurs in 
triton-insoluble forms, probably associated with cytoskeletal components within non-transfected 
HEK293 cells. Curiously, when cells overexpress WT Sph1A and MT Sph1A, this tendency is not 
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changed but the PPP1CA bands in the insoluble fractions become less intense for both constructs 
used (Figure 15). Moreover, it is important to emphasize that PPP1CA recruitment to insoluble 
fractions is even more reduced when cells are transfected with MT Sph1A, in which the Sph1A 
PPP1 BM is disrupted (ratio 0.4 %, Figure 15). A less PPP1CA recruitment to the insoluble 
fraction in cells overexpressing MT Sph1A suggests a decreased Sph1A/PPP1 interaction due to 
RVTF motif disruption. Nevertheless, explaining the global reduction in PPP1CA recruitment to 
the insoluble fractions observed for both constructs is not so easy. Indeed, loading problems and 
other experimental problems could not be excluded as no loading control was used and this 
experiment needs further replication. Other possible explanations include a true reduction in 
endogenous PPP1CA levels in transfected cells due to decreased PPP1CA expression and/or 
enhanced degradation. Other tests should be performed in order to clarify this result. 
Finally, concerning α-syn, a 16 kDa band with low intensity can be clearly detected in the 
triton-soluble fraction of non-transfected cells (Figure 15). Moreover, a quite diffuse and fade band 
can also be identified in the insoluble fraction, under control conditions (Figure 15). Unluckily, the 
band corresponding to α-syn is maintained in the soluble fraction, even after WT Sph1A and MT 
Sph1A overexpression, and no clear recruitment can be observed to the triton-insoluble fractions 
(Figure 15). This absence of α-syn recruitment to Sph1A inclusions is not positive but is not 
surprising. Indeed, in the present work, Sph1A was overexpressed alone, without α-syn co-
transfection, contrarily to literature that consistently documents Sph1/α-syn co-transfections as a 
means to produce α-syn/Sph1-positive inclusions. 
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Figure 15 - PPP1CA and α-syn recruitment to Sph1A inclusion bodies in HEK293 cells. Upper panel: Western blot 
analysis of triton-soluble (Sol) and triton-insoluble (Insol) fractions produced through fractionation of non-transfected 
HEK293 cells (CT) and HEK293 cells overexpressing WT Sph1A (WT Sph1A). Lower panel: Western blot analysis of 
triton-soluble (Sol) and triton-insoluble (Insol) fractions produced through fractionation of non-transfected HEK293 cells 
(CT) and HEK293 cells overexpressing MT Sph1A (MT Sph1A). For both panels, the proteins detected and their 
molecular weight are depicted at the left. It is also indicated the protein mass and sample volume loaded in each lane. 
Soluble and insoluble fractions of the same experimental condition were loaded with equal volume to assure the 
maintenance of the relative proportion of each protein in the two fractions. The percentage values are the ratios between 
the volume of each insoluble band and the volume of its corresponding soluble band, being a measure of protein 
recruitment to the insoluble fraction. Ratios depicted as ** could not be determined.   
Taken together, these preliminary results suggest that, upon transfection, Sph1A exists in a 
soluble and in an insoluble, aggregated form, and this tendency is not altered by RVTF mutation. 
Furthermore, in cells overexpressing Sph1A, endogenous PPP1CA suffers redistribution, being its 
recruitment to the insoluble fractions decreased upon mutation of Sph1A PPP1 BM in comparison 
to cells transfected with WT Sph1A. Finally, α-syn is mainly retained in the soluble fraction both in 
non-transfected cells and in cells transfected with Sph1A (WT or MT), does not suggesting its 
recruitment to Sph1A inclusion bodies in cells overexpressing Sph1A alone.  
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5. Discussion 
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Sph1A is a Sph1 isoform and an aggregation-prone protein able to interact with α-syn and 
Sph1, being relevant for LBs formation
[74]
. Nevertheless, the regulatory mechanisms that modulate 
Sph1A aggregation are poorly understood. Previous studies have already documented the 
regulatory role of GSK3β and CKII for Sph1 aggregation[88, 90, 91]. As Sph1A displays similarities 
with Sph1, its major isoform, it seems legit to assume that reversible phosphorylation may also 
modulate Sph1A aggregation as well. 
Thence, the present work confirms the novel interaction between Sph1A and PPP1 and 
addresses the influence of PPP1 activity on Sph1A aggregation and inclusion bodies formation. 
Nevertheless, it is also discussed the putative effect of Sph1A in modifying PPP1 activity, through 
PPP1 targeting to specific subcellular compartments.  
5.1 ESTABLISHING SYNPHILIN-1A AS A PPP1-INTERACTING PROTEIN 
Protein reversible phosphorylation is the most studied post-translational modification able to 
modulate protein activity in eukaryotic cells. Nevertheless, there are no studies documenting the 
effect of phosphorylation on Sph1A aggregation. In light of that, after a yeast two hybrid screen 
from a human brain library, Sph1A was identified as a putative PPP1 interactor, establishing the 
first link between a Sph1 isoform and a phosphatase
[105]
. This interaction was further confirmed by 
biochemical methods
[107]
. Interestingly, it was shown in an independent study that Sph1 
phosphorylation state is sensitive to okadaic acid treatment, a well established phosphatases 
inhibitor, but no reference or association to PPP1 were made
[90]
.  
Aiming the development of the work initiated by Dr.ª Sara Esteves, in the present work, 
Sph1A/PPP1 interaction is confirmed in ex vivo conditions and the potential role of Sph1A as a PIP 
is discussed
[96]
. Indeed, the present work shows that, upon Sph1A overexpression in HEK293 cells, 
PPP1CA and PPP1CC interact with and are targeted to Sph1A inclusion bodies. Furthermore, this 
targeting could be blocked by mutation of Sph1A PPP1 BM, RVTF, thus being dependent on the 
conserved Sph1A PPP1 BM. This evidence suggests Sph1A putative role as a PIP. 
In order to discuss Sph1A classification as a PIP, PIP features must be clearly defined. To be 
considered a PIP, proteins must (1) interact with PPP1 both in vitro and in vivo, (2) containing a 
conserved and functional PPP1 BM responsible for the interaction with PPP1
[102]
. Moreover, 
PIP/PPP1 interaction must be significant for cell function, being the PIP a PPP1 substrate itself, a 
PPP1 activity modulator or a protein able to alter PPP1 subcellular localization
[96]
. Taking into 
account the previous PIP definition, Sph1A may be considered a PIP as (1) is able to interact with 
PPP1 (PPP1CA and PPP1CC) both in vitro
[107]
 and ex vivo, (2) this interaction is dependent on the 
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Sph1A PPP1 BM (RVTF) and (3) alters PPP1 subcellular localization, targeting the phosphatase to 
Sph1A inclusion bodies. Although it is clear that Sph1A targets PPP1 to inclusion bodies, the 
present study does not address other relevant questions, particularly if Sph1A is also a PPP1 
substrate or if it is able to modulate PPP1 activity, besides targeting the phosphatase.  
Assuming that Sph1A is actually a functional PIP, new hypotheses arise as Sph1A/PPP1 
interaction may uncover new regulatory aspects behind Sph1A aggregation and LBs formation, 
relevant for PD pathogenesis. Nevertheless, Sph1A should also interact and target PPP1 in non-
pathologic conditions. Therefore, this interaction could also determine some aspects of Sph1A 
physiology within normal neurons.  
Despite the solid evidence that Sph1A could be classified as a PIP, the present study has 
some pitfalls. Indeed, Sph1A/PPP1 interaction was confirmed through a Sph1A overexpression 
approach in HEK293 cells. HEK293 cells are not a neuronal lineage and protein overexpression 
produces non-physiologic conditions. However, this approach was useful in the present work 
because the objectives were mainly at the molecular level, particularly the study of protein 
interactions, which is often sufficiently general to be addressed in different cell types. Moreover, 
according to literature, all the initial studies concerning Sph1A were performed in HEK293 cells 
due to their advantages in terms of manipulation, resilience and transfection efficiency. On the 
other hand, protein overexpression is non-physiologic but is a useful tool to produce some PD-
related features, as PD is characterized by the accumulation of abnormal proteins. Finally, the 
overexpression approach was not overused as PPP1 levels were not manipulated in any experiment 
of this work. PPP1 endogenous levels were always considered.  
5.2 PPP1 TARGETING TO SPH1A INCLUSION BODIES – IMPLICATIONS FOR INCLUSION 
BODIES FORMATION 
Assuming that Sph1A is a novel PIP able to, at least, target PPP1 to Sph1A inclusion bodies, 
it seems legit to expect some molecular/cellular effect of this targeting to inclusion bodies 
formation.  
In order to address this hypothesis, the present study has investigated Sph1A aggregation 
pattern, in conditions that allow Sph1A/PPP1 interaction and upon blockage of PPP1 recruitment to 
Sph1A inclusion bodies, through Sph1A PPP1 BM mutagenesis. According to the results obtained, 
PPP1 recruitment influences Sph1A inclusion bodies formation, at least in HEK293 cells. Indeed, 
when PPP1 is not targeted to Sph1A aggregates, the formation of bigger aggregates is favored. On 
the other hand, when PPP1 is allowed to interact with Sph1A, small aggregates are the most 
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abundant inclusions. Furthermore, the global process of Sph1A aggregation seems to be accelerated 
by PPP1 targeting blockage as bigger aggregates are massively formed earlier. Taken together, 
these evidences suggest that PPP1, through Sph1A targeting, is able to modulate inclusion bodies 
formation within HEK293 cells overexpressing Sph1A.   
PPP1 ability to modulate and, most specifically, to decrease Sph1A aggregation within cells 
is something expected and possibly could be explained taking into account Sph1A ability to target 
PPP1 to inclusion bodies. This explanation is attractive because reinforces the classification of 
Sph1A as a PIP by demonstrating a cellular effect of Sph1A/PPP1 interaction. Actually, during 
Sph1A aggregation in transfected HEK293 cells, PPP1 (possibly PPP1CA and PPP1CC) may be 
targeted to the forming inclusion bodies due to Sph1A RVTF motif. This change in PPP1 
subcellular localization may concentrate PPP1 within Sph1A aggregates, favoring protein 
dephosphorylation within Sph1A inclusion bodies. By decreasing protein phosphorylation state in 
aggregates, PPP1 could decrease protein-protein interactions leading to reduced Sph1A 
aggregation. This could explain why WT Sph1A has a slower aggregation pattern in which the 
bigger aggregates only significantly appear for higher post-transfection periods. On the other hand, 
if PPP1 could not be recruited, for example due to Sph1A PPP1 BM disruption, this protective 
effect may be lost because there is an imbalance between phosphorylation and dephosphorylation 
within inclusion bodies. In that case, Sph1A aggregate-related proteins become 
hyperphosphorylated, enhancing protein-protein interactions and Sph1A aggregation. Thence, 
bigger aggregates are formed earlier, explaining the phenotype seen in cells overexpressing MT 
Sph1A.  
Two main arguments corroborate the process suggested above. First, there are several PIPs 
known to target PPP1 to specific subcellular compartments and for specific targets, enhancing 
PPP1 activity in these compartments and in the close proximity of the desired targets
[96]
. Second, a 
previous study concerning CKII and Sph1 has already demonstrated that higher Sph1 
phosphorylation by CKII is able to enhance inclusion bodies formation
[90]
. In order to explain that 
observation, authors suggested that Sph1/α-syn interaction could be influenced by the 
phosphorylation state of these proteins. Most particularly, higher phosphorylation levels were 
associated to an enhanced Sph1/α-syn interaction[90]. Thence, it is not surprising if the inverse 
process happens for Sph1A, a Sph1 isoform, and PPP1, a phosphatase. Actually, it is likely that 
PPP1 decreases Sph1/α-syn interaction by decreasing the phosphorylation state of the proteins 
referred. 
Despite the attractiveness of this hypothesis, actually the fractionation experiment 
documented in the present work failed to demonstrate bigger α-syn recruitment to inclusion bodies 
53 
 
in cells transfected with a Sph1A form incapable of interact with PPP1. Nevertheless, this was just 
a preliminary test. Indeed, the absence of α-syn recruitment to inclusion bodies could be caused by 
an experimental limitation, probably the overexpression of Sph1A alone without α-syn co-
transfection.  
5.3 NOCODAZOLE EXPERIMENT – INTERESTING TOPICS 
After the identification of alterations in Sph1A aggregation pattern in conditions of PPP1 
BM disruption, Sph1A ability to produce aggresomes was evaluated because some of the big 
aggregates formed seem to be perinuclear. The ability of Sph1 to form aggresomes upon 
proteasome inhibition is well established
[40]
. Nevertheless, there is no information concerning 
Sph1A and, in the present study, no proteasome inhibitors were used. Thence, if Sph1A was really 
able to form true aggresomes without proteasome inhibition, this could be a quite interesting topic, 
demonstrating a crucial difference between Sph1A and Sph1 and strengthening the definition of 
Sph1A as an aggregation-prone isoform. 
Unluckily, both Nocodazole treatment and γ-tubulin staining fail to clearly demonstrate the 
true nature of Sph1A aggregates as aggresomes. However, some ideas and observations resulting 
from these experiments should be emphasized. 
First, it is worthy to refer that Nocodazole and, most prominently, DMSO did produce a 
slight effect and, interestingly, this only occurred in cells transfected with MT Sph1A, being 
unequivocally absent in cells transfected with WT Sph1A. Therefore, cells overexpressing MT 
Sph1A display some sensitiveness to manipulation, although it could not be specifically attributed 
to cytoskeleton dynamics. It is not easy to explain the alterations observed. Indeed, DMSO is a 
solvent and probably could interfere with Sph1A passive aggregation but it was massively diluted 
in the cells medium. Thence, a more general effect might be happening, perhaps on cytoskeleton 
dynamics or even in some cellular mechanism. Indeed, literature suggested the ability of DMSO to 
promote hyperphosphorylation of cytoskeletal components, although this event requires DMSO 
concentrations higher than the one applied in the present study
[109]
. Whatever the true explanation 
for that, it is certain that Nocodazole and DMSO treatment induce sufficient stress in MT Sph1A 
overexpressing cells to disrupt the formation of medium aggregates, most prominently under 
DMSO treatment. 
Second, in terms of γ-tubulin staining, it is rather odd that non-transfected cells reveal 
readily identifiable centrosomes while transfected cells containing aggregates fail to do so, in the 
same coverslip. Although it could be an artificial result due to transfection or even excessive 
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background, one could not exclude that centrosomes actually might not be accessible in cells 
containing aggregates. Indeed, protein aggregation may hinder antibody interaction with γ-tubulin 
by surrounding the epitope. Even more likely is the possibility that transfection and protein 
aggregation cause sufficient stress to HEK293 cells to induce apoptosis in a large proportion of 
them. In this case, it is not strange that centrosomes could not be detected. 
Despite all problems and inconclusive results from this section of the study, Figure 11 should 
be emphasized because it suggests the association between Sph1A and the microtubules network. 
This observation was interpreted as Sph1A aggregates transport to the perinuclear space to form 
aggresomes but other interesting explanations may be suggested. Indeed, Sph1A could be a protein 
able to interact with microtubules under physiological conditions, which is consistent with previous 
observations
[110]
 as well as with Sph1 role as scaffold protein and a putative modulator of synaptic 
vesicle trafficking
[75]
.     
5.4 WHAT HAVE WE LEARNED ABOUT SYNPHILIN-1? WHAT COULD WE EXPECT? 
This work studies the functional consequences of Sph1A/PPP1 interaction, particularly in 
inclusion bodies formation, suggesting that PPP1 targeting to aggregates acts like a protective 
mechanism, decreasing protein aggregation. Nevertheless, besides the implications for inclusion 
bodies formation, Sph1A/PPP1 interaction should also occur under physiological conditions, 
probably having astonishing consequences in presynaptic terminals dynamics.   
Indeed, Sph1 is a well known α-syn-interacting protein thought to modulate α-syn function 
in the presynaptic terminals with possible implications in neurotransmitters release
[75]
. If PPP1 
modulates Sph1/α-syn interaction, has it seems to occur for inclusion bodies formation, the same 
event should occur under physiological conditions, possibly regulating dopamine release
[75]
. This 
hypothesis becomes even more attractive if one considers that α-syn does not have a PPP1 BM but 
Sph1, one of its major interacting proteins, has
[107]
.   
Another interesting idea that should be emphasized is spinophilin function in PD. 
Spinophilin is a PIP known to play a crucial function in PPP1c targeting for dendritic spines within 
medium spiny neurons
[111]
. Furthermore, it is suggested that spinophilin associates with the 
cytoskeleton, particularly F-actin, regulating PPP1 specificity toward ion channels and other 
substrates
[111]
. Upon dopamine depletion, there is an enhancement of spinophilin/PPP1 interaction, 
which leads to a decreased PPP1 activity in dendritic spines, producing hyperphosphorylation of 
several substrate proteins, impairing plasticity in PD patients
[112]
.  
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Taking into account the data concerning spinophilin, there are astonishing similarities 
between spinophilin and Sph1. Indeed, Sph1 is thought to be a scaffold protein without catalytic 
activity just as spinophilin. Moreover, the present work clearly demonstrates Sph1 ability to 
participate in PPP1 targeting within cells and some studies also suggest Sph1 ability to interact 
with lipid rafts, synaptic vesicles and also with cytoskeletal components. Therefore, Sph1 could be 
faced as a putative “pre-synaptic spinophilin”, targeting PPP1 to the presynaptic terminals, with 
implications in α-syn functions, neurotransmitters release and perhaps other trafficking and 
signaling mechanisms. Hence, the observations described in this study have provided cues that 
probably will help to uncover the true Sph1 functions in dopaminergic neurons.      
Finally, the findings present in this study may have important implications not only to better 
understand inclusion bodies formation but also other events of PD pathogenesis. Indeed, PD is a 
neurodegenerative disorder and a major hallmark of such pathologies is protein 
hyperphosphorylation, which could be due to decreased phosphatases activity. When it comes to 
PD, it is already described a decreased activity of PPP2 caused by phosphatase sequestering into 
LBs, leading to hyperphosphorylation of several PPP2 substrates, with implication in the 
pathological process
[113]
. As Sph1A proved its ability to recruit PPP1 to inclusion bodies, it is 
attractive to think that a massive recruitment of PPP1 to Sph1A aggregates could lead to an 
alteration in PPP1 intracellular localization, becoming enriched within aggregates and decreasing 
its availability in other subcellular compartments. In such a case, PPP1 activity would become 
higher within aggregates and decreased in other compartments, with putative implications in the 
phosphorylation state of numerous PPP1 substrates in a way similar to PPP2. 
In summary, aiming the study of Sph1A/PPP1 interaction and its implications for inclusion 
bodies formation, the present study has uncovered novel cues, probably relevant to understand 
Sph1A/PPP1 interaction in a physiological context and in PD pathogenesis.   
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6. Conclusions and Future Work 
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The Sph1A/PPP1 complex, recently identified in human brain, is a novel complex with 
unknown function and was the starting point for the present work. Indeed, after its identification 
through a high throughput technique (yeast two hybrid), it was important to validate its existence as 
well as to explore its functional implications, particularly for inclusion bodies formation, as Sph1A 
has long been referred as a key player in PD.  
Interestingly, Sph1A/PPP1 interaction proved to actually occur in ex vivo conditions as both 
PPP1CA and PPP1CC are recruited to Sph1A inclusion bodies within cells overexpressing Sph1A. 
Moreover, this interaction is specific and dependent on the Sph1A PPP1 BM RVTF as a point 
mutation in this motif is sufficient to hamper the interaction and block PPP1 targeting to Sph1A-
containing aggregates. 
After validation of the existence of Sph1A/PPP1 complex in HEK293 cells, the present study 
also uncovered an important role of this complex for inclusion bodies formation. Actually, 
disruption of the PPP1 BM present in Sph1A produced a more aggregative phenotype in HEK293 
cells, favoring the formation of bigger aggregates and accelerating protein aggregation. Such event 
was attributed to decreased PPP1 targeting to inclusion bodies upon PPP1 BM disruption, leading 
to hyperphosphorylation of inclusion body-related proteins, enhancing protein-protein interactions. 
Thus, Sph1A/PPP1 complex seems to be implicated in the regulation of the interactions between 
some proteins present in inclusion bodies, probably Sph1 and α-syn.  
As Sph1A is known to be an aggregation-prone Sph1 isoform, its ability to form aggresomes 
without proteasome inhibitors administration to cells was also studied. Unluckily, Sph1A does not 
seem able to form bona fide aggresomes, at least without proteasome inhibition, as Sph1A 
aggregation does not show significant sensitiveness to drugs that block microtubule dynamics. 
Also, a marked co-localization between Sph1A aggregates and MTOC could not be clearly 
demonstrated in our tests. 
Therefore, as conclusion, Sph1A is indeed able to interact with PPP1CA and PPP1CC within 
cells and Sph1A/PPP1 complex plays a role in PPP1 targeting, at least to inclusion bodies, 
enhancing protein aggregation when disrupted. This suggests that Sph1A/PPP1 complex modulates 
the interaction between some PD-related proteins, probably Sph1 and α-syn, having implications 
not only for Lewy bodies formation but also for other events of PD pathogenesis and, perhaps, even 
in physiological conditions. Indeed, by regulating Sph1/α-syn association, the Sph1A/PPP1 
complex might modulate neurotransmitters release and other presynaptic processes in the 
presynaptic terminals of dopaminergic neurons. 
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This work has uncovered so many cues concerning the regulation of Sph1 activities both 
under physiological and pathological conditions that a lot of questions should be addressed in the 
future. Therefore, in order to continue this work, some important future tasks are the following: 
 To assess the effect of WT Sph1A and MT Sph1A in cells viability, possibly measuring 
LDH release by transfected cells; 
 To perform Nocodazole experiment in conditions of proteasome inhibition and perhaps 
using other microtubule drugs, such as colchicine; 
 To repeat the experiment that addressed the putative co-localization between Sph1A 
aggregates and MTOC but using other MTOC markers, such as vimentin or pericentrin; 
 To evaluate Sph1A effect on PPP1 activity to address if Sph1A is a PPP1 inhibitor, using 
assays for phosphatase activity quantification; 
 To address if PPP1 is able to directly dephosphorylate Sph1A; 
 To assess if Sph1/α-syn interaction is really enhanced upon disruption of the Sph1A/PPP1 
complex, using immunofluorescence or fractionation experiments in cells co-transfected 
with Sph1A and α-syn; 
 To test Sph1A co-localization with microtubules markers; 
 To establish and apply other suitable cell lineages in all these studies besides HEK293 
cells, such as SH-SY5 or H4. 
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I. CULTURE MEDIA AND SOLUTIONS 
Cell Culture Solutions and Immunocytochemistry: 
PBS (1X) 
For a final volume of 500 mL, dissolve one pack of Modified Dulbecco’s Phosphate Buffered 
Saline Pack (Pierce) in deionized H2O. Final composition: 
- 8 mM Sodium Phosphate 
- 2 mM Potassium Phosphate  
- 40 mM NaCl 
- 10 mM KCl 
Sterilize by filtering through a 0.2 µm filter and store at 4ºC. 
1 mg/mL Poly-L-ornithine solution (10X) 
To a final volume of 10 mL, dissolve in deionized H2O 100 mg of poly-L-ornithine (Sigma-
Aldrich, Portugal). 
4% Paraformaldehyde fixative solution 
For a final volume of 100 mL, add 4 g of paraformaldehyde to 25 mL of deionized H2O. Dissolve 
by heating the mixture at 58 ºC while stirring. Add 1-2 drops of 1 M NaOH to clarify the solution 
and filter (0.2 µm). 
DMEM medium 
For a final volume of 1L, dissolve one pack of DMEM powder (with L-glutamine and 4500 mg 
glucose/L, Sigma-Aldrich) in deionized H2O and add: 
- NaHCO3 (Sigma-Aldrich) 3.7 g 
Adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
Complete DMEM 
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For a final volume of 1L, when preparing DMEM medium adjust to pH 7.4 and before sterilizing 
add: 
- 100 mL (10% v/v) Fetal Bovine Serum (FBS) 
- Antibiotics (5 mL) 
 100 U/mL penicillin 
 100 mg/mL streptomycin 
DMEM Components 
Amino acids:  Concentration (mg/L) 
L-Arginine hydrochloride  84 
L-Cystine  62.6 
L-Glutamine  584 
Glycine  30 
L-Histidine hydrochloride  42 
L-Isoleucine  105 
L-Leucine  105 
L-Lysine hydrochloride  146 
L-Methionine  30 
L-Phenylalanine  66 
L-Serine  42 
L-Threonine  95 
L-Tryptophan  16 
L-Tyrosine  103.79 
L-Valine  94 
Vitamins: 
Choline chloride  4 
D-Calcium pantothenate  4 
Folic acid  4 
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Niacinamide  4 
Riboflavin  0.4 
Thiamine hydrochloride  4 
Myo-Inositol 7.2 
Inorganic Salts: 
Calcium Chloride (CaCl2.2H2O)  200 
Magnesium Sulfate (MgSO4.7H2O)  97.67 
Potassium Chloride  400 
Sodium Chloride  6400 
Sodium Phosphate monobasic (NaH2PO4.2H2O)  109 
Other components: 
D-Glucose  4500 
Phenol Red  15.9 
SDS-PAGE and Immunoblotting Solutions: 
LGB (Lower Gel Buffer) 
To 900 mL of deionized H2O add: 
- 181.65 g Tris 
- 4 g SDS 
Mix until the solutes have dissolved. Adjust pH to 8.9 and adjust volume to 1 L with deionized 
H2O. 
UGB (Upper Gel Buffer) 
To 900 mL of deionized H2O add: 
- 75.69 g Tris 
Mix until the solute has dissolved. Adjust pH to 6.8 and adjust volume to 1L with deionized H2O. 
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30% Acrylamide/ 0.8% Bisacrylamide 
To 70 mL of deionized H2O add: 
- 29.2 g Acrylamide 
- 0.8 g Bisacrylamide 
Mix until the solutes have dissolved. Adjust volume to 100 mL with deionized H2O. Store at 4 ºC. 
Loading Gel Buffer 
- 250 mM Tris-HCl (pH 6.8) 
- 8% SDS 
- 40% Glycerol 
- 2% 2-mercaptoethanol 
- 0.01% Bromophenol blue 
1X Running Buffer 
- 25 mM Tris-HCl (pH 8.3) 
- 250 mM Glycine  
- 0.1% SDS 
1X Transfer Buffer 
- 25 mM Tris-HCl (pH 8.3) 
- 192 mM Glycine  
- 20% Methanol 
1X TBS 
- 10 mM Tris-HCl (pH 8.0) 
- 150 mM NaCl 
Adjust pH to 8.0 with HCl and adjust volume to 1L with deionized H2O. 
1X TBST 
- 10 mM Tris-HCl (pH 8.0) 
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- 150 mM NaCl  
- 0.05% Tween 
Adjust pH to 8.0 with HCl and adjust volume to 1L with deionized H2O. 
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II. ANTIBODIES 
Table 1 - Antibodies and dilutions. (IF, Immunofluorescence; WB, Western Blot; Rb, Rabbit; Ms, Mouse; IR, Infrared) 
 
  
Antibodies Dilutions Company Secondary antibody Dilutions 
PPP1CA 
1:500 (IF) 
Homemade 
Texas Red Anti-Rb 1:300 
1:2500 (WB) 
Anti-Rb (IR) 
Odyssey CLx 
1:5000 
PPP1CC 
1:1000 (IF) 
Homemade 
Texas Red Anti-Rb 1:300 
1:5000 (WB) 
Anti-Rb (IR) 
Odyssey CLx 
1:5000 
β-Tubulin 1:1000 (WB) Sigma-Aldrich 
Anti-Ms (IR) 
Odyssey CLx 
1:5000 
GFP 1:1000 (WB) Sigma-Aldrich 
Anti-Ms (IR) 
Odyssey CLx 
1:5000 
α-Synuclein 1:1000 (WB) Sigma-Aldrich 
Anti-Rb (IR) 
Odyssey CLx 
1:5000 
γ-Tubulin 1:5000 (IF) Sigma-Aldrich Alexa 594 Anti-Ms 1:500 
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III. BCA STANDARDS 
Table 2 - BCA standards. 
Standards BSA (µL) 1% SDS (µL) Protein mass (µg) WR (µL) 
P0 - 25 0 200 
P1 0.5 24.5 1 200 
P2 1 24 2 200 
P3 2.5 22.5 5 200 
P4 5 20 10 200 
P5 10 15 20 200 
 
The BSA solution used for standards preparation has a concentration of 2 mg/mL.   
The Working Reagent (WR) is prepared adding 1 mL of Solution B to each 50 mL of 
Solution A.  
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IV. PLASMIDS  
 
 
Figure 16 - pEGFP-N1 vector map and MCS (Clontech). This eukaryotic expression vector was used to express GFP-
tagged WT Sph1A and GFP-tagged MT Sph1A in mammalian cells (HEK293 cells). As depicted, the fusion protein is 
expressed with an EGFP tag at the C-terminus of the target protein.  
 
